<html>
<head><title>
Prepared and filed by St Ives Financial
</title>
</head>
<body bgcolor="#FFFFFF">
<page>
<p align="center"><font size="2" face="serif">As filed with the Securities and Exchange Commission on June 24, 2005 </font></p>
<p align="right"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Registration No. 333-&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p align="center"><font size="2" face="serif">SECURITIES AND EXCHANGE COMMISSION<br>
Washington, D.C. 20549</font></p>
<p align="center"><font size="2" face="serif">FORM S-8</font></p>
<p align="center"><font size="2" face="serif">REGISTRATION STATEMENT UNDER  THE SECURITIES ACT OF 1933</font></p>
<p align="center"><font size="2" face="serif"><u>CRYSTALLEX INTERNATIONAL CORPORATION</u><br>
(Exact name of registrant as specified in its charter)</font></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td width="33%" align="center" valign="bottom"><font size="2" face="serif"><u>Canada</u></font></td>
    <td width="33%">&nbsp;</td>
    <td align="center" valign="bottom"><font size="2" face="serif"><u>98-0152628</u></font></td>
  </tr>
  <tr>
    <td align="center" valign="bottom"><font size="2" face="serif">(State or
    other jurisdiction of&nbsp;<br>
    incorporation or organization)    </font></td>
    <td>&nbsp;</td>
    <td align="center" valign="bottom"><font size="2" face="serif">&nbsp;(I.R.S.
    Employer<br>
    Identification No.)    </font></td>
  </tr>
</table>
<p align="center"><font size="2" face="serif"><u>18 King Street East, Suite 1210,
      Toronto, Ontario, Canada M5C 1C4</u><br>
(Address of principal executive offices) (zip code)</font></p>
<p align="center"><font size="2" face="serif"><u>Incentive Share Option Plan,
      Share Option Agreements, and</u><br>
<u>Directors Remuneration Plan</u><br>
(Full title of plans)</font></p>
<p align="center"><font size="2" face="serif">Corporation Service Company<br>
1090 Vermont Avenue, N.W., Suite 430 <br>
<u>Washington, D.C. 20005</u><br>
(Name and address of agent for service)</font></p>
<p align="center"><font size="2" face="serif"><u>(888) 690-2882</u><br>
(Telephone number, including area code, of agent for service)</font></p>
<p align="center"><font size="2" face="serif">Copy to:<br>
Lawrence W. Koltun, Esq.<br>
Koltun &amp; King, P.C.<br>
1146 19th Street, N.W., Suite 250 <br>
Washington, D.C. 20036      </font></p>
<p align="left"><font size="2" face="serif">This registration statement contains a resale prospectus, pursuant to General Instruction C thereof, relating to both this registration statement as well as Registrations No. 333-7568, 333-9876, and 333-12890.</font></p>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<a name="p?"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="center"><font size="2" face="serif"><u>CALCULATION OF REGISTRATION FEE</u></font></p>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="bottom" bgcolor="#FFFFFF">
<td align="left"><b><font size="1" face="serif">Title of securities to<br>
  be registered</font></b></td>
<td width="2%" align="left">&nbsp;</td>
<td width="1%" align="right">&nbsp;</td>
<td width="13%" align="right"><b><font size="1" face="serif">Amount to be<br>
  registered</font></b></td>
<td width="2%" align="left">&nbsp;</td>
<td width="1%" align="right">&nbsp;</td>
<td width="13%" align="right"><b><font size="1" face="serif">Proposed maximum <br>
  offering price <br>
  per share (1)</font></b></td>
<td width="2%" align="left">&nbsp;</td>
<td width="1%" align="right">&nbsp;</td>
<td width="13%" align="right"><b><font size="1" face="serif">Proposed <br>
  maximum <br>
  aggregate <br>
  offering price (1)</font></b></td>
<td width="2%" align="left">&nbsp;</td>
<td width="1%" align="right">&nbsp;</td>
<td width="13%" align="right"><b><font size="1" face="serif">Amount of</font><font size="1"><br>
      <font face="serif"> fee (1)</font></font></b></td>
<td width="2%" align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td><hr noshade size="1"></td>
<td></td>
<td></td>
<td><hr noshade size="1"></td>
<td></td>
<td><hr noshade size="1"></td>
<td><hr noshade size="1"></td>
<td></td>
<td><hr noshade size="1"></td>
<td><hr noshade size="1"></td>
<td></td>
<td><hr noshade size="1"></td>
<td><hr noshade size="1"></td>
<td></td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="bottom" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif">Options to acquire common <br>
shares without par value (1)</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">16,279,500</font><br>
  <font size="2" face="serif">Options</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="bottom">
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="bottom" bgcolor="#ffffff">
<td align="left"><font size="2" face="serif">Common shares without par <br>
value
    issuable upon exercise of <br>
        stock options
    (2)</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">6,779,500</font><br>
  <font size="2" face="serif">common shares</font></td>
<td align="left">&nbsp;</td>
<td align="right"><font size="2" face="serif">$</font></td>
<td align="right"><font size="2" face="serif"> (3</font></td>
<td align="left"><font size="2" face="serif">)</font></td>
<td align="right"><font size="2" face="serif">$</font></td>
<td align="right"><font size="2" face="serif">  14,943,355</font></td>
<td align="left">&nbsp;</td>
<td align="right"><font size="2" face="serif">$</font></td>
<td align="right"><font size="2" face="serif">  4,503.55</font></td>
<td align="left"><font size="2" face="serif">(4)</font></td>
</tr>
<tr valign="bottom">
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="bottom" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif">Common shares without par <br>
value
    issuable upon exercise of <br>
        stock</font> <font size="2" face="serif">Options
    (5)</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">2,000,000 common shares</font></td>
<td align="left">&nbsp;</td>
<td align="right"><font size="2" face="serif">$</font></td>
<td align="right"><font size="2" face="serif"> (3</font></td>
<td align="left"><font size="2" face="serif">)</font></td>
<td align="right"><font size="2" face="serif">$</font></td>
<td align="right"><font size="2" face="serif">  2,655,735</font></td>
<td align="left">&nbsp;</td>
<td align="right"><font size="2" face="serif">$</font></td>
<td align="right"><font size="2" face="serif">  701.11</font></td>
<td align="left"><font size="2" face="serif">(6)</font></td>
</tr>
<tr valign="bottom">
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="bottom" bgcolor="#ffffff">
<td align="left"><font size="2" face="serif">Common shares without par <br>
value
    issuable upon exercise of <br>
        stock Options (7)</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">13,263,162</font><br>
  <font size="2" face="serif">common shares</font></td>
<td align="left">&nbsp;</td>
<td align="right"><font size="2" face="serif">$</font></td>
<td align="right"><font size="2" face="serif">3.72 (7)</font></td>
<td align="left">&nbsp;</td>
<td align="right"><font size="2" face="serif">$</font></td>
<td align="right"><font size="2" face="serif">49,338,962 (7)</font></td>
<td align="left">&nbsp;</td>
<td align="right"><font size="2" face="serif">$</font></td>
<td align="right"><font size="2" face="serif">5,807.20</font></td>
<td align="left"><font size="2" face="serif"> (8)</font></td>
</tr>
<tr valign="bottom">
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="bottom" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif">Common shares without par <br>
value (9)</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">600,000</font><br>
  <font size="2" face="serif">common shares</font></td>
<td align="left">&nbsp;</td>
<td align="right"><font size="2" face="serif">$</font></td>
<td align="right"><font size="2" face="serif"> (3</font></td>
<td align="left"><font size="2" face="serif">)</font></td>
<td align="right"><font size="2" face="serif">$</font></td>
<td align="right"><font size="2" face="serif">  320,086</font></td>
<td align="left">&nbsp;</td>
<td align="right"><font size="2" face="serif">$</font></td>
<td align="right"><font size="2" face="serif">  88.98</font></td>
<td align="left"><font size="2" face="serif">(10)</font></td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left"><font size="2" face="serif">Total</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">22,642,662</font><br><font size="2" face="serif">common shares</font></td>
<td align="left">&nbsp;</td>
<td align="right"><font size="2" face="serif">$</font></td>
<td align="right"><font size="2" face="serif"> (3</font></td>
<td align="left"><font size="2" face="serif">)</font></td>
<td align="right"><font size="2" face="serif">$</font></td>
<td align="right"><font size="2" face="serif">67,258,138</font></td>
<td align="left">&nbsp;</td>
<td align="right"><font size="2" face="serif">$</font></td>
<td align="right"><font size="2" face="serif">11,100.84</font><br>
  <font size="2" face="serif">(4), (6), (8), (10)</font></td>
<td align="left">&nbsp;</td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">(1)</font></td>
<td align="left">
<font size="2" face="serif"> Consisting of options to purchase common shares under the registrant&#8217;s Incentive Share Option Plan adopted in 1997, as amended in 1998, 2000, 2001, 2002, 2004, and 2005.  There is no fee associated with the options to be registered, as the common shares underlying the options are being registered herein.</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">(2)</font></td>
<td align="left">
<font size="2" face="serif"> Includes common shares, and options to acquire such shares, previously registered under Registrations Nos. 333-7568 and 333-9876.  Pursuant to Rule 416 under the Securities Act of 1933, the number of shares also includes shares issuable pursuant to antidilution provisions relating to the securities that are convertible or exercisable into common shares being registered hereby.  The registrant is using a resale prospectus for both such registration statements pursuant to Rule 429.</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">(3)</font></td>
<td align="left">
<font size="2" face="serif"> The determination of the proposed maximum offering prices per share is set forth in Registrations Nos. 333-7568, 333-9876, and 333-12890.</font></td>
</tr>
</table>
<p align="center"><font size="2">ii</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page> <a name="p?"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p>&nbsp;</p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"><font size="2" face="serif">(4)</font></td>
<td align="left">
<font size="2" face="serif"> The registrant paid $4,228.75 in filing fees upon filing Registration No. 333-7568 and an additional $274.80 in filing fees upon filing Registration No. 333-9876.</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">(5)</font></td>
<td align="left">
<font size="2" face="serif"> Includes common shares, and options to acquire such shares, previously registered under Registration No. 333-12890.  Pursuant to Rule 416 under the Securities Act of 1933, the number of shares also includes shares issuable pursuant to antidilution provisions relating to the securities that are convertible or exercisable into common shares being registered hereby.  The registrant is using a resale prospectus for such registration statement pursuant to Rule 429.</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">(6)</font></td>
<td align="left">
<font size="2" face="serif"> The registrant paid $701.11 in filing fees in connection with such shares upon filing Registration No. 333-12890.</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">(7)</font></td>
<td align="left">
<font size="2" face="serif"> The offering price for the 7,689,458 shares is determined pursuant to Rule 457(c) and (h) based upon the average of the high and low prices reported for the registrant&#8217;s common shares on the American Stock Exchange as of June 22, 2005. Pursuant to Rule 416 under the Securities Act of 1933, the number of shares also includes shares issuable pursuant to antidilution provisions relating to the securities that are convertible or exercisable into common shares being registered hereby. The registrant is using a resale prospectus for such shares pursuant to Rule 429.</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">(8)</font></td>
<td align="left">
<font size="2" face="serif"> Paid herewith.</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">(9)</font></td>
<td align="left">
<font size="2" face="serif"> Includes common shares previously registered in Registration No. 333-12890 under the registrant&#8217;s Directors Remuneration Plan.  The registrant is using a resale prospectus for such registration statement pursuant to Rule 429.</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">(10)</font></td>
<td align="left">
<font size="2" face="serif"> The registrant paid $88.98 in filing fees in connection with such shares upon filing Registration No. 333-12890.</font></td>
</tr>
</table>
<p align="center"><font face="serif" size="2">iii</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<a name="p?"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="center"><font size="2" face="serif">PART I</font></p>
<p align="left"><font size="2" face="serif">The information specified by Part
    I of Form S-8 has been omitted from this Registration Statement on Form S-8
    with respect to offers and sales of up to 8,381,407 common shares without
    par value
(the &#8220;Shares&#8221;) of Crystallex International Corporation pursuant to
its Incentive Share Option Plan (the &#8220;Option Plan&#8221;), consulting or
option agreements not subject to such plan, and the Directors Remuneration Plan
(the &#8220;Directors Plan&#8221;) referred to herein.  The document will be
sent or given to the Option Plan&#8217;s and Directors Plan&#8217;s participants
and the persons subject to such consulting or option agreements.</font></p>
<p align="left"><font size="2" face="serif">In accordance with General Instruction
    C to Form S-8 as promulgated by the Securities and Exchange Commission, Crystallex
    has prepared this resale prospectus with respect to offers and sales of its
    Shares by its affiliates pursuant to the Option Plan. This prospectus also
    covers the offers and sales by Crystallex affiliates or non-affiliates of
    up to 422,800 restricted Shares issued upon their exercise, prior to the
    date of this prospectus, of options issued pursuant to the Option Plan, and
    the
    offers and sales of unregistered Shares acquired prior to the date of this
prospectus by Crystallex affiliates pursuant to the Directors Plan.</font></p>
<p align="left"><font size="2" face="serif">This prospectus has been prepared in accordance with the requirements of General Instruction C to Form S-8 and Part I of Form F-3.</font></p>
<p align="center"><font face="serif" size="2">iv</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<a name="p?"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="center"><font size="2" face="serif">CRYSTALLEX INTERNATIONAL CORPORATION</font></p>
<p align="center"><font size="2" face="serif">Organized under the Laws of Canada</font></p>
<p align="center"><font size="2" face="serif">RESALE PROSPECTUS</font></p>
<p align="center"><font size="2" face="serif">8,804,207 Common Shares</font></p>
<p align="left"><font size="2" face="serif">Certain selling shareholders who
    are affiliates of Crystallex International Corporation may use this prospectus
    to sell their Crystallex common shares that they may acquire when they exercise
    stock options to acquire up to an aggregate of 7,274,750 common shares that
    Crystallex has granted or may grant to them under its Incentive Share Option
    Plan adopted in 1997 (as modified in 1998, 2000, 2001, 2002, 2004, and 2005)
    and up to 842,500 common shares that Crystallex may issue pursuant to written
    consulting options or agreements not subject to such plan (collectively,
    the &#8220;Options&#8221;).  In addition, certain selling shareholders who
    are Crystallex directors may use this prospectus to sell periodically up
    to an aggregate of 264,157 common shares that Crystallex issued or authorized
    for issuance to them pursuant to Crystallex&#8217;s Directors Remuneration
    Plan. Furthermore, certain selling shareholders, some of whom are not Crystallex
    affiliates,
    may use
    this prospectus to resell 422,800 Crystallex common shares that they
    received upon the exercise of Options prior to the date of this prospectus.  <i>See</i> &#8220;Selling
    Shareholders.&#8221;  Crystallex will not receive any sales proceeds when
    a selling shareholder sells his shares.</font></p>
<p align="left"><font size="2" face="serif">The selling shareholders may sell all or any portion of these Crystallex common shares in one or more transactions through ordinary brokerage transactions, in private, negotiated transactions, or through any other means described in the section entitled &#8220;Plan of Distribution&#8221; beginning on page 13. <b></b>The sales may be made at market prices prevailing at the time of sale, at negotiated prices, or at fixed prices, which may be changed.  These transactions may or may not involve brokers or dealers.  Crystallex will not receive any sales proceeds when these selling shareholders convert their convertible notes or convertible debentures or sell their common shares, but Crystallex will receive the exercise price of any warrants that the
selling shareholders exercise.</font></p>
<p align="left"><font size="2" face="serif">Crystallex lists the common shares
    for trading on The American Stock Exchange and on The Toronto Stock Exchange
    under the symbol KRY. As of June 23, 2005, the closing price for the common
    shares on The American Stock Exchange was US$3.72 and on The Toronto Stock
    Exchange
was Cdn$4.65.</font></p>
<p align="left"><font size="2" face="serif"><b>It may be risky to purchase the common shares.  See &#8220;Risk Factors&#8221; beginning on page 4.</b></font></p>
<p align="left"><font size="2" face="serif">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus.  Any representation to the contrary is a criminal offense.</font></p>
<p align="center"><font size="2" face="serif">*               *               *</font></p>
<p align="center"><font size="2" face="serif">The date of this prospectus is June 24, 2005.</font></p>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<a name="contents"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="center"><font size="2" face="serif">TABLE OF CONTENTS</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p align="left"><font size="2" face="serif"></font></p>
<table width="102%" cellspacing="0" cellpadding="0" border="0">
  <tr valign="bottom">
    <td align="left"><font size="2" face="serif"><b>Item</b></font></td>
    <td width="10%" align="center"><font size="2" face="serif">&nbsp; <b>Page</b></font></td>
  </tr>
<tr valign="bottom">
  <td align="left">&nbsp;</td>
  <td align="center">&nbsp;</td>
</tr>
<tr valign="bottom">
<td align="left"><a href="#p3"><font size="2" face="serif">SUMMARY OF CRYSTALLEX           </font></a></td>
<td align="center"><a href="#p3"><font size="2" face="serif">3</font></a></td>
</tr>

  <tr valign="bottom">
    <td align="left">&nbsp;</td>
    <td align="center">&nbsp;</td>
  </tr>
<tr valign="bottom">
<td align="left"><a href="#p4"><font size="2" face="serif">RISK FACTORS</font></a></td>
<td align="center"><a href="#p4"><font size="2" face="serif"> 4</font></a></td>
</tr>

  <tr valign="bottom">
    <td align="left">&nbsp;</td>
    <td align="center">&nbsp;</td>
  </tr>
<tr valign="bottom">
<td align="left"><a href="#p5"><font size="2" face="serif">HOW TO OBTAIN MORE INFORMATION</font></a></td>
<td align="center"><a href="#p5"><font size="2" face="serif">5 </font></a></td>
</tr>

  <tr valign="bottom">
    <td align="left">&nbsp;</td>
    <td align="center">&nbsp;</td>
  </tr>
<tr valign="bottom">
<td align="left"><a href="#p7"><font size="2" face="serif">ENFORCEABILITY OF
    CIVIL LIABILITIES AGAINST CRYSTALLEX</font></a></td>
<td align="center"><a href="#p7"><font size="2" face="serif"> 7</font></a></td>
</tr>

  <tr valign="bottom">
    <td align="left">&nbsp;</td>
    <td align="center">&nbsp;</td>
  </tr>
<tr valign="bottom">
<td align="left"><a href="#p7"><font size="2" face="serif">FORWARD-LOOKING STATEMENTS</font></a></td>
<td align="center"><font size="2" face="serif"><a href="#p7">7</a></font></td>
</tr>

  <tr valign="bottom">
    <td align="left">&nbsp;</td>
    <td align="center">&nbsp;</td>
  </tr>
<tr valign="bottom">
<td align="left"><a href="#p8"><font size="2" face="serif">CAPITALIZATION AND INDEBTEDNESS</font></a></td>
<td align="center"><a href="#p8"><font size="2" face="serif"> 8</font></a></td>
</tr>

  <tr valign="bottom">
    <td align="left">&nbsp;</td>
    <td align="center">&nbsp;</td>
  </tr>
<tr valign="bottom">
<td align="left"><a href="#p8"><font size="2" face="serif">RECENT DEVELOPMENTS</font></a></td>
<td align="center"><a href="#p8"><font size="2" face="serif">8</font></a></td>
</tr>

  <tr valign="bottom">
    <td align="left">&nbsp;</td>
    <td align="center">&nbsp;</td>
  </tr>
<tr valign="bottom">
<td align="left"><a href="#p9"><font size="2" face="serif">RECENT PRICE HISTORY   </font></a></td>
<td align="center"><a href="#p9"><font size="2" face="serif">9</font></a></td>
</tr>

  <tr valign="bottom">
    <td align="left">&nbsp;</td>
    <td align="center">&nbsp;</td>
  </tr>
<tr valign="bottom">
<td align="left"><a href="#p10"><font size="2" face="serif">SHARE CAPITAL</font></a></td>
<td align="center"><a href="#p10"><font size="2" face="serif"> 10</font></a></td>
</tr>

  <tr valign="bottom">
    <td align="left">&nbsp;</td>
    <td align="center">&nbsp;</td>
  </tr>
<tr valign="bottom">
<td align="left"><a href="#p12"><font size="2" face="serif">THE SECURITIES BEING OFFERED</font></a></td>
<td align="center"><a href="#p12"><font size="2" face="serif">12</font></a></td>
</tr>

  <tr valign="bottom">
    <td align="left">&nbsp;</td>
    <td align="center">&nbsp;</td>
  </tr>
<tr valign="bottom">
<td align="left"><a href="#p13"><font size="2" face="serif">USE OF PROCEEDS</font></a></td>
<td align="center"><a href="#p13"><font size="2" face="serif">13</font></a></td>
</tr>

  <tr valign="bottom">
    <td align="left">&nbsp;</td>
    <td align="center">&nbsp;</td>
  </tr>
<tr valign="bottom">
<td align="left"><a href="#p13"><font size="2" face="serif">PLAN OF DISTRIBUTION  </font></a></td>
<td align="center"><a href="#p13"><font size="2" face="serif">13</font></a></td>
</tr>

  <tr valign="bottom">
    <td align="left">&nbsp;</td>
    <td align="center">&nbsp;</td>
  </tr>
<tr valign="bottom">
<td align="left"><a href="#p15"><font size="2" face="serif">DESCRIPTION OF SECURITIES TO BE
    REGISTERED  </font></a></td>
<td align="center"><a href="#p15"><font size="2" face="serif">15</font></a></td>
</tr>

  <tr valign="bottom">
    <td align="left">&nbsp;</td>
    <td align="center">&nbsp;</td>
  </tr>
<tr valign="bottom">
<td align="left"><a href="#p15"><font size="2" face="serif">SELLING SHAREHOLDERS</font></a></td>
<td align="center"><a href="#p15"><font size="2" face="serif">15</font></a></td>
</tr>

  <tr valign="bottom">
    <td align="left">&nbsp;</td>
    <td align="center">&nbsp;</td>
  </tr>
<tr valign="bottom">
<td align="left"><a href="#p19"><font size="2" face="serif">LEGAL MATTERS</font></a></td>
<td align="center"><a href="#p19"><font size="2" face="serif"> 19</font></a></td>
</tr>

  <tr valign="bottom">
    <td align="left">&nbsp;</td>
    <td align="center">&nbsp;</td>
  </tr>
<tr valign="bottom">
<td align="left"><a href="#p19"><font size="2" face="serif">EXPERTS  </font></a></td>
<td align="center"><a href="#p19"><font size="2" face="serif">19</font></a></td>
</tr>
</table>
<p align="center"><font face="serif" size="2">2</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<a name="p3"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="left"><font size="2" face="serif">You should rely only on the information contained in this prospectus and the information incorporated into this prospectus by reference (<i>see</i> &#8220;Incorporation of Documents by Reference&#8221;) and not upon anything else in deciding whether to purchase the common shares offered through this prospectus.  Neither Crystallex nor any of the selling shareholders will authorize providing you with any other information in connection with your purchase.  This prospectus does not offer to sell or solicit an offer to buy any security other than the common shares that this prospectus offers.  In addition, this prospectus does not offer to sell or solicit any offer to buy any common shares to any person in any jurisdiction where it is unlawful to
make this offer to or solicit an offer from a person in that jurisdiction.</font></p>
<p align="left"><font size="2" face="serif"><b><u>Note:</u></b>  Unless otherwise indicated, all amounts in this prospectus are stated in U.S. dollars.</font></p>
<p align="center"><font size="2" face="serif">SUMMARY OF CRYSTALLEX</font></p>
<p align="left"><font size="2" face="serif">Crystallex was incorporated on May 22, 1984 under the Company Act of the province of British Columbia, Canada.  On January 23, 1998, its corporate existence was continued under the Canada Business Corporation Act (&#8220;CBCA&#8221;), thereby bringing Crystallex under the jurisdiction of the CBCA as if it was originally incorporated under the CBCA.  Crystallex trades as a public company on the TSX and the AMEX under the symbol &#8220;KRY&#8221;.  It engages in exploring, developing, and mining for gold, with its primary focus in Venezuela, and in evaluating mineral property acquisitions in various locations around the world.  Crystallex is currently producing gold from the Tomi concession in Venezuela and processing ore from the Tomi concession
at Crystallex&#8217;s Revemin Mill in Venezuela. Crystallex also has rights to extract ore from its La Victoria mine in Venezuela and is pursuing permits to develop an underground mine at its Albino 1 concession in the Kilometre 88 region of Venezuela.  Crystallex also has secured rights to develop the gold deposits known as Las Cristinas 4, 5, 6 and 7, also in the Kilometre 88 region.  </font></p>
<table width="60%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td align="left" valign="bottom"><b><font size="1" face="serif">Property</font></b></td>
<td width="2%" align="left" valign="bottom">&nbsp;</td>
<td width="1%" align="right" valign="bottom">&nbsp;</td>
<td width="28%" align="center" valign="bottom"><b><font size="1" face="serif">Location</font></b></td>
<td width="2%" align="left" valign="bottom">&nbsp;</td>
<td width="1%" align="right" valign="bottom">&nbsp;</td>
<td width="20%" align="center" valign="bottom"><b><font size="1" face="serif">Percentage Interest, </font><font size="1"><br>
      <font face="serif">Direct or Indirect</font></font></b></td>
<td width="2%" align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
  <td align="left"><hr size="1" noshade></td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="center"><hr size="1" noshade></td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right"><hr size="1" noshade></td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left"><font size="2" face="serif">Las Cristinas</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="center"><font size="2" face="serif">Venezuela</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">   100</font></td>
<td width="5%" align="left"><font size="2" face="serif">%<sup>(1)</sup></font></td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif">Tomi</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="center"><font size="2" face="serif">Venezuela</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">100</font></td>
<td align="left"><font size="2" face="serif">%</font></td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left"><font size="2" face="serif">Revemin Mill</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="center"><font size="2" face="serif">Venezuela</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">93</font></td>
<td align="left"><font size="2" face="serif">%</font></td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif">Albino 1</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="center"><font size="2" face="serif">Venezuela</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">100</font></td>
<td align="left"><font size="2" face="serif">%<sup>(2)</sup></font></td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left"><font size="2" face="serif">Lo Increible</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="center"><font size="2" face="serif">Venezuela</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">51</font></td>
<td align="left"><font size="2" face="serif">%<sup>(3)</sup></font></td>
</tr>
</table>
<p>&nbsp;</p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;<sup>(1) </sup></font></td>
<td align="left"><font size="2" face="serif">Refers to an agreement granted to Crystallex to mine the property.  <i>See</i> &#8220;Risk Factors&#8221; in Crystallex&#8217;s Form 40-F for the year ended December 31, 2004.</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;<sup>(2) </sup></font></td>
<td align="left"><font size="2" face="serif">In early 2005, Crystallex was informed that its concession rights for Albino 1 have been rescinded.  Crystallex is appealing this rescission. <i> See &#8220;</i>Risk Factors&#8221; in Crystallex&#8217;s Form 40-F for the year ended December 31, 2004.</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;<sup>(3) </sup></font></td>
<td align="left"><font size="2" face="serif">Crystallex owns 100% of El Callao Mining Corp., which indirectly owns 51% of the Lo Increible property.</font></td>
</tr>
</table>
<p align="center"><font size="2">3</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page> <a name="p4"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="left"><font size="2" face="serif">Details with respect to all of the foregoing properties are provided in the documents incorporated by reference.  <i>See</i> &#8220;How to Obtain More Information.&#8221;</font></p>
<p align="left"><font size="2" face="serif">Crystallex&#8217;s principal executive office, registered office, and principal place of business are located at 18 King Street East, Suite 1210, Toronto, Ontario, M5C 1C4, telephone number (416) 203-2448.</font></p>
<p align="center"><font size="2" face="serif">RISK FACTORS</font></p>
<p align="left"><font size="2" face="serif">Your purchase of the common shares may be risky.  In addition to the other information contained in this prospectus or incorporated by reference into this prospectus, please read carefully the risk factors contained in Crystallex&#8217;s Annual Report on Form 40-F for its Fiscal Year Ended December 31, 2004, together with the following factors, before purchasing common shares offered by this prospectus:</font></p>
<p align="left"><font size="2" face="serif"><b>Crystallex has incurred recent losses.</b></font></p>
<p align="left"><font size="2" face="serif">Crystallex incurred net losses in
    2004, 2003, 2002, and 2001. Crystallex&#8217;s profitability depends, among
    other things, on the price of gold, the level of gold production, cash operating
    costs and other factors discussed in &#8220;Risk Factors.&#8221;  Substantially
    all of these factors are beyond Crystallex&#8217;s control. <b></b>As part
    of the preparation of its financial statements for the year ended December
    31, 2004, Crystallex undertook a detailed review of the carrying value of
    each of its mineral properties as well as related deferred exploration costs
    and its plant and equipment. Based on this review, and reflecting the impact
    of its recently received notice of the termination of its Albino 1 concession,
    Crystallex incurred a write-down of $32 million for the year ended December
    31, 2004. The write-down included $10.5 million for Albino, $13.8 million
    for Revemin, $3.6 million for Tomi, and $4.1 million for other properties.</font></p>
<p align="left"><font size="2" face="serif"><b>Crystallex has authorized for issuance a large number of shares, which, if issued in significant amounts, could result in dilution of share ownership and a reduction in share price.</b></font></p>
<p align="left"><font size="2" face="serif">As at June 24, 2005, Crystallex has
    authorized the issuance of more than 20.6 million common shares
    that have not yet been issued for payment of certain property purchases and
    related indebtedness, the exercise of stock options, finder's fees, the exercise
    of warrants issued in private placements, placement agent's fees for a private
    placement, and exercise of warrants issued for convertible notes and broker's
    fees. Furthermore, Crystallex may issue additional common shares from time
    to time in the future. If Crystallex issues a substantial number of those
    new shares, it could substantially dilute the ownership interest of Crystallex&#8217;s
    current shareholders, based upon the 193,793,337 Crystallex shares outstanding
    as of June 24,
2005. In addition, given Crystallex&#8217;s average daily trading volume
of approximately 617,200 shares on the American Stock Exchange (&#8220;AMEX&#8221;)
(Consolidated Market) and approximately 597,000 shares on the Toronto Stock Exchange
(&#8220;TSX&#8221;) for the period January 1, 2004 through December 31, 2004,
the sale of these shares could provide enough selling pressure to depress the
share price of Crystallex&#8217;s common shares. </font></p>
<p align="center"><font size="2" face="serif">4</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page> <a name="p5"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="center"><font size="2" face="serif">HOW TO OBTAIN MORE INFORMATION</font></p>
<p align="left"><font size="2" face="serif">We file reports and other information
    with the Securities and Exchange Commission. You may read any document we
    file at the SEC&#8217;s public reference rooms at 450 Fifth Street, N.W.
    in Washington, D.C. 20549. Please call the SEC toll free at 1-800-SEC-0330
    for information about its public reference rooms. The SEC maintains an Internet
    site, <u>http://www.sec.gov,</u> that contains reports, proxy and information
    statements, and other information regarding issuers that file electronically
    with the SEC. A copy of our SEC filings since October, 2002, including a
    copy of this prospectus, the registration statement (and amendments to the
    registration statement) relating to this prospectus and our annual report
    on Form 40-F and Form 40-F/A-No. 1 for our year ended December 31, 2004,
    our Forms 6-K submitted to the SEC since November 4, 2002, all amendments
    to
    any of
    these
    filings
    or reports, and all future documents or reports that we will file or submit
    to the SEC, are or will be also available to you free of charge at the SEC&#8217;s
    Internet site.</font></p>
<p align="left"><font size="2" face="serif">We have filed with the SEC a registration statement on Form S-8 under the Securities Act of 1933 relating to this prospectus. This prospectus does not contain all of the information in the registration statement.  We have omitted certain parts of the registration statement, as permitted by the rules and regulations of the SEC.  You may inspect and copy the registration statement, including exhibits, at the SEC&#8217;s public reference facilities.  Our statements in this prospectus are not necessarily complete about the contents of any contract or other document. You should refer to the copy of each contract or other document we have filed as an exhibit to the registration statement for complete information.</font></p>
<p align="left"><font size="2" face="serif">The SEC allows us to &#8220;incorporate by reference&#8221; into this prospectus information we file with the SEC. This means that we can disclose important information to you by referring you to those documents. This information we incorporate by reference is considered a part of this prospectus, and later information we file with the SEC will automatically update and supersede this information. We incorporate by reference the documents listed below and any future filings we make with the SEC under Sections 12, 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934 until this offering is completed: </font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td width="93%" align="left"><font size="2" face="serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Crystallex's
    Annual Report on Form 40-F and on Form 40-F/A &#150; No. 1 for the fiscal
    year ended December 31, 2004, filed under Section 13 of the Securities Exchange
    Act.</font></td>
</tr>

<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
    description of Crystallex's common shares without par value contained in
    Crystallex&#8217;s registration statement under Section 12(b) of the Securities
    Exchange Act on Form 8-A (Registration No. 1-14620). </font></td>
</tr>
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>

<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Crystallex&#8217;s
    registration statement under Section 12(b) of the Securities Exchange Act
    on Form 8-A of rights to acquire Crystallex&#8217;s common shares (Registration
    No. 1-14620).  </font></td>
</tr>
</table>
<p align="center"><font size="2" face="serif">5</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page> <a name="p6"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>

<table width="100%" cellspacing="0" cellpadding="0" border="0">

<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td width="93%" align="left"><font size="2" face="serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;The
    Report of Foreign Issuer on Form 6-K furnished to the SEC on April 1, 2005,
    on May 12, 2005, on May 13, 2005, on May 20, 2005, on June 22, 2005,<b></b>and
    on June 24, 2005. Crystallex&#8217;s report on Form 6-K furnished on May
    12, 2005, contains its unaudited financial statements for the quarter ended
    March 31, 2005.</font></td>
</tr>
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>

<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
    subsequent annual reports filed by Crystallex on Form 20-F, Form 40-F, or
    Form 10-K, and all subsequent filings on Forms 10-Q and 8-K filed by Crystallex
    under Sections 12, 13, 14 or 15(d) of the Securities Exchange Act, after
    the date of this prospectus and before the termination of the offering are
    deemed incorporated by reference into and be a part of this prospectus from
    the date of filing such documents.</font></td>
</tr>
</table>
<p align="left"><font size="2" face="serif">Crystallex may incorporate by reference into this prospectus any Form 6-K that it furnishes to the SEC under Sections 12, 13, 14 or 15(d) of the Securities Exchange Act after the date of this prospectus and before the offering is completed, and make that Form 6-K a part of this prospectus from the date it files the form, but only to the extent that Crystallex identifies in the Form 6-K that it is being incorporated by reference into this prospectus. </font></p>
<p align="left"><font size="2" face="serif">Crystallex will provide to each person, including any beneficial owner, to whom a prospectus is delivered, a copy of any or all of the information that Crystallex incorporates by reference in this prospectus but is not delivered with the prospectus, free of charge by contacting Crystallex&#8217;s Secretary, Daniel R. Ross, orally or in writing, at our principal offices, which are located at 18 King Street East, Suite 1210, Toronto, Ontario, M5C 1C4, telephone number (416) 203-2448, or by contacting investor relations at <u>info@crystallex.com</u>.  However, Crystallex will not provide a copy of exhibits to items that it incorporates by reference unless it specifically incorporates those exhibits by reference.</font></p>
<p align="left"><font size="2" face="serif">You should rely only on the information provided in this prospectus or any prospectus supplement. We have not authorized anyone else to provide you with different information. The selling shareholders are not making an offer of these securities in any state or other jurisdiction where the offer is not permitted. This prospectus does not offer to you any security other than the common shares that this prospectus specifically offers.  Information contained on our Web site is not a part of this prospectus.  </font></p>
<p align="center"><font size="2" face="serif">6</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page> <a name="p7"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="center"><font size="2" face="serif">ENFORCEABILITY OF CIVIL LIABILITIES AGAINST CRYSTALLEX</font></p>
<p align="left"><font size="2" face="serif">The enforcement by purchasers of the common shares offered in this prospectus of civil liabilities under the federal securities laws of the United States may be adversely affected by the fact that Crystallex is a Canadian corporation, many of its directors and shareholders are residents of Canada, and the majority of Crystallex&#8217;s assets and all or a substantial portion of the assets of such other persons are located outside the United States.  As a result, it may be difficult for purchasers to effect service of process within the United States upon such persons or to realize against them in the United States upon judgments of courts of the United States predicated upon civil liabilities under securities laws of the United States.  McMillan
Binch Mendelsohn LLP, Canadian counsel for Crystallex, advised Crystallex that there is doubt as to the enforceability in Canada against Crystallex or its directors or officers who are not residents of the United States in original actions or in actions for enforcement of judgments of United States courts of liabilities predicated upon federal securities laws of the United States.  </font></p>
<p align="center"><font size="2" face="serif">FORWARD-LOOKING STATEMENTS</font></p>
<p align="left"><font size="2" face="serif">All statements other than statements of historical fact included in this prospectus regarding Crystallex&#8217;s financial position, business strategy and plans and objectives of management of Crystallex for future operations, are forward-looking statements.  When used in this prospectus, words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;may&#8221; and similar expressions, as they relate to Crystallex or its management, identify forward-looking statements.  These forward-looking statements are based on the beliefs of Crystallex&#8217;s management, as well as assumptions made by and information currently available to
Crystallex&#8217;s management.  Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as those disclosed under &#8220;Risk Factors&#8221; in this prospectus, including but not limited to, competitive factors and pricing pressures, changes in legal and regulatory requirements, technological change or difficulties, product development risks, commercialization and trade difficulties and general economic conditions.  Such statements reflect the current views of Crystallex with respect to future events and are subject to these and other risks, uncertainties and assumptions relating to the operations, results of operations, and growth strategy of Crystallex.  All subsequent written and oral forward-looking statements
attributable to Crystallex or persons acting on its behalf are expressly qualified in their entirety by this paragraph.</font></p>
<p align="center"><font size="2" face="serif"><i>[text continues on next page]</i></font></p>
<p align="center">&nbsp;</p>
<p align="center">&nbsp;</p>
<p align="center">&nbsp;</p>
<p align="center"><font size="2" face="serif">7</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page> <a name="p8"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="center"><font size="2" face="serif">CAPITALIZATION AND INDEBTEDNESS<br>
As of April 30, 2005<br>
(unaudited)</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top" bgcolor="#FFFFFF">
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td colspan="4" align="center" valign="bottom"><b><font size="1" face="serif">Notes and Debentures</font></b></td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left">&nbsp;</td>
<td align="left" width="2%">&nbsp;</td>
<td width="1%" align="right">&nbsp;</td>
<td align="center" valign="bottom"><b><font size="1" face="serif">&nbsp;Actual</font></b></td>
<td width="2%" align="left">&nbsp;</td>
<td width="1%" align="right">&nbsp;</td>
<td align="center" valign="bottom"><b><font size="1" face="serif">&nbsp; As Adjusted(1)</font></b></td>
<td width="2%" align="left">&nbsp;</td> </tr>
<tr valign="top">
  <td></td>
  <td></td>
  <td><hr noshade size="1">
  </td>
  <td><hr noshade size="1">
  </td>
  <td></td>
  <td><hr noshade size="1">
  </td>
  <td><hr noshade size="1">
  </td>
  <td></td>
</tr>
<tr valign="top" bgcolor="#ffffff">
  <td align="left"><font size="2" face="serif"><u>Debt</u></font></td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left"><div style="margin-left: 6%; text-indent: -3%"><font size="2" face="serif"> Current
    portion of long-term debt</font></div></td>
<td align="left">&nbsp;</td>
<td align="right"><font size="2" face="serif">$</font></td>
<td width="10%" align="right"><font size="2" face="serif">  4,258,470</font></td>
<td align="left">&nbsp;</td>
<td align="right"><font size="2" face="serif"> $</font></td>
<td width="10%" align="right"><font size="2" face="serif">   4,258,470</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><div style="margin-left: 6%; text-indent: -3%"><font size="2" face="serif"> Total
    long-term debt, net of current portion</font></div></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">79,210,959</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif"> 79,210,959</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td></td>
<td></td>
<td><hr noshade size="1"></td>
<td><hr noshade size="1"></td>
<td></td>
<td><hr noshade size="1"></td>
<td><hr noshade size="1"></td>
<td></td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left"><div style="margin-left: 9%; text-indent: -3%"><font size="2" face="serif">Total
    Debt</font></div></td>
<td align="left">&nbsp;</td>
<td align="right"><font size="2" face="serif">          $</font></td>
<td align="right"><font size="2" face="serif"> 83,469,429</font></td>
<td align="left">&nbsp;</td>
<td align="right"><font size="2" face="serif"> $</font></td>
<td align="right"><font size="2" face="serif"> 83,469,429</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td></td>
<td></td>
<td><hr noshade size="2"></td>
<td><hr noshade size="2"></td>
<td></td>
<td><hr noshade size="2"></td>
<td><hr noshade size="2"></td>
<td></td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif"><u>Stockholders&#8217; equity</u></font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif"> Common
    shares (unlimited shares authorized; 192,631,619 issued and outstanding)</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">           311,855,538</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">  311,855,538 </font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left"><font size="2" face="serif"> Contributed Surplus</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif"> 30,649,009</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">30,649,009</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif"> Cumulative Translation Adjustment</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">             11,958,981</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">11,958,981</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left"><font size="2" face="serif"> Deficit</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif"> (218,474,832</font></td>
<td align="left"><font size="2" face="serif">)</font></td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">(218,474,832</font></td>
<td align="left"><font size="2" face="serif">)</font></td>
</tr>
<tr valign="top">
<td></td>
<td></td>
<td><hr noshade size="1"></td>
<td><hr noshade size="1"></td>
<td></td>
<td><hr noshade size="1"></td>
<td><hr noshade size="1"></td>
<td></td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif">Total stockholders&#8217; equity</font></td>
<td align="left">&nbsp;</td>
<td align="right"><font size="2" face="serif"> $</font></td>
<td align="right"><font size="2" face="serif"> 135,988,696</font></td>
<td align="left">&nbsp;</td>
<td align="right"><font size="2" face="serif">$</font></td>
<td align="right"><font size="2" face="serif"> 135,988,696</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td></td>
<td></td>
<td><hr noshade size="1"></td>
<td><hr noshade size="1"></td>
<td></td>
<td><hr noshade size="1"></td>
<td><hr noshade size="1"></td>
<td></td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left"><font size="2" face="serif">Total Capitalization</font></td>
<td align="left">&nbsp;</td>
<td align="right"><font size="2" face="serif"> $</font></td>
<td align="right"><font size="2" face="serif"> 219,458,125</font></td>
<td align="left">&nbsp;</td>
<td align="right"><font size="2" face="serif">$</font></td>
<td align="right"><font size="2" face="serif"> 219,458,125</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td></td>
<td></td>
<td><hr noshade size="2"></td>
<td><hr noshade size="2"></td>
<td></td>
<td><hr noshade size="2"></td>
<td><hr noshade size="2"></td>
<td></td>
</tr>
</table>
<p align="left"><font size="2" face="serif">_______</font></p>
<p align="left"><font size="2" face="serif"><sup> (1)</sup>  Does not include the exercise into Crystallex common shares of any options, special warrants, or warrants outstanding as of April 30, 2005, or that may be issued thereafter.</font></p>
<p align="center"><font size="2" face="serif">RECENT DEVELOPMENTS</font></p>
<p align="left"><font size="2" face="serif">Prior to 2004, Crystallex issued approximately 800,000 common shares to Standard Bank of London (&#8220;SBL&#8221;) as partial settlement of its outstanding loan with SBL. Crystallex and SBL also entered into an agreement whereby SBL agreed not to sell the Crystallex shares it had obtained as the loan repayment in large blocks but instead disposed of the shares in an orderly fashion over time (Orderly Disposition Agreement or &#8220;ODA&#8221;). </font></p>
<p align="left"><font size="2" face="serif">As provided by the ODA, on final disposition of the shares issued to SBL, SBL would retain any aggregate sale proceeds in excess of the issue price of the shares and certain agreed interest (excess proceeds) and apply the excess proceeds against any obligations owing to SBL by Crystallex, whereas any final aggregate shortfall would require payment by Crystallex to SBL to cover the shortfall. The excess proceeds or shortfall could only be determined and applied when all shares subject to the ODA had been disposed.</font></p>
<p align="left"><font size="2" face="serif">SBL sold the last block of the shares by the end of May 2004.  It had cumulative excess proceeds from sale of all of the shares of approximately $4 million.  Crystallex and SBL agreed to allocate the excess proceeds against outstanding commodity contract obligations that Crystallex had with SBL.  Crystallex accounted for the allocation of proceeds against outstanding commodity contract obligations as a reduction of its commodity contract loss (that is, an income statement item) in its June 30, 2004, and September 30, 2004, unaudited interim financial statements.  Crystallex disclosed this accounting in the notes to the financial statements for both periods.</font></p>
<p align="center"><font size="2" face="serif">8</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page> <a name="p9"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="left"><font size="2" face="serif">However, in preparing its full year financial statements for its year ended December 31, 2004, Crystallex accounted for this transaction as an increase in its share capital rather than an income statement item.  Crystallex reflected this accounting treatment in it year-end 2004 audited financial statement and in its disclosure of its quarterly financial information contained in its year-end Management&#8217;s Discussion and Analysis (&#8220;MD&amp;A&#8221;).  Both the year-end audited financial statements and MD&amp;A are contained in exhibits attached to Crystallex&#8217;s Annual Report on Form 40-F.  <i>See </i>&#8220;How To Obtain More Information.&#8221; </font></p>
<p align="center"><font size="2" face="serif">RECENT PRICE HISTORY</font></p>
<p align="left"><font size="2" face="serif">Crystallex's common shares trade on the TSX and on the AMEX under stock symbol &#8220;KRY&#8221;.  The discussion contained in this section is based upon information provided by the Toronto Stock Exchange or American Stock Exchange, as applicable.  The following tables presents additional closing price information:</font></p>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td align="left"><font size="1" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td colspan="4" align="center" valign="bottom"><font size="1" face="serif"><b>Toronto Stock Exchange</b></font><br>
  <font size="1" face="serif"><b>CDN $</b></font></td>
<td align="center" valign="bottom">&nbsp;</td>
<td align="center" valign="bottom">&nbsp;</td>
<td colspan="4" align="center" valign="bottom"><font size="1" face="serif"><b>American Stock Exchange</b></font><br>
  <font size="1" face="serif"><b>US$</b></font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top">
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td colspan="4" align="center" valign="bottom"><hr size="1" noshade></td>
  <td align="center" valign="bottom">&nbsp;</td>
  <td align="center" valign="bottom">&nbsp;</td>
  <td colspan="4" align="center" valign="bottom"><hr size="1" noshade></td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td align="left"><font size="1" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="center" valign="bottom"><font size="1" face="serif"><b>High</b></font></td>
<td align="center" valign="bottom">&nbsp;</td>
<td align="center" valign="bottom">&nbsp;</td>
<td align="center" valign="bottom"><font size="1" face="serif"><b>Low</b></font></td>
<td align="center" valign="bottom">&nbsp;</td>
<td align="center" valign="bottom">&nbsp;</td>
<td align="center" valign="bottom"><font size="1" face="serif"><b>High</b></font></td>
<td align="center" valign="bottom">&nbsp;</td>
<td align="center" valign="bottom">&nbsp;</td>
<td align="center" valign="bottom"><font size="1" face="serif"><b>Low</b></font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td align="left"><font size="1" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right"><hr size="1" noshade></td>
<td align="left">
  <hr size="1" noshade></td>
<td align="left">&nbsp;</td>
<td align="right"><hr size="1" noshade></td>
<td align="left">
  <hr size="1" noshade></td>
<td align="left">&nbsp;</td>
<td align="right"><hr size="1" noshade></td>
<td align="left">
  <hr size="1" noshade></td>
<td align="left">&nbsp;</td>
<td align="right"><hr size="1" noshade></td>
<td align="left">
  <hr size="1" noshade></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif"><b>Fiscal Quarter Ended</b></font></td>
<td align="left" width="2%">&nbsp;</td>
<td width="1%" align="right">&nbsp;</td>
<td width="14%" align="left"><font size="2" face="serif">&nbsp;</font></td>
<td width="2%" align="left">&nbsp;</td>
<td width="1%" align="right">&nbsp;</td>
<td width="14%" align="left"><font size="2" face="serif">&nbsp;</font></td>
<td width="2%" align="left">&nbsp;</td>
<td width="1%" align="right">&nbsp;</td>
<td width="14%" align="left"><font size="2" face="serif">&nbsp;</font></td>
<td width="2%" align="left">&nbsp;</td>
<td width="1%" align="right">&nbsp;</td>
<td width="14%" align="left"><font size="2" face="serif">&nbsp;</font></td>
<td width="2%" align="left">&nbsp;</td> </tr>
<tr valign="top" bgcolor="#ffffff">
<td align="center"><font size="2" face="serif">March 31, 2003</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">2.44</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">1.25</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">1.55</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">0.85</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="center"><font size="2" face="serif">June 30, 2003</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">2.86</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">1.00</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">2.15</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">0.69</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="center"><font size="2" face="serif">September 30, 2003</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">4.48</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">2.01</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.25</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">1.38</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="center"><font size="2" face="serif">December 31, 2003</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">4.15</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">2.90</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.20</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">2.17</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="center"><font size="2" face="serif">March 31, 2004</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">5.00</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.15</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.75</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">2.36</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="center"><font size="2" face="serif">June 30, 2004</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">4.12</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">2.75</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.14</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">1.99</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="center"><font size="2" face="serif">September 30, 2004</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">4.21</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">2.70</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.37</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">2.05</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="center"><font size="2" face="serif">December 31, 2004</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">5.41</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.82</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">4.52</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.02</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="center"><font size="2" face="serif">March 31, 2005</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">5.00</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.80</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.99</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.05</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif"><b>Months Ended</b></font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="center"><font size="2" face="serif">December 31, 2004</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">4.50</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">4.05</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.76</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.30</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="center"><font size="2" face="serif">January 31, 2005</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">4.28</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.83</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.51</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.11</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="center"><font size="2" face="serif">February 28, 2005</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">4.45</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.80</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.63</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.05</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="center"><font size="2" face="serif">March 31, 2005</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">5.00</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">4.08</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.99</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.28</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="center"><font size="2" face="serif">April 30, 2005</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">5.17</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">4.35</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">4.19</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.57</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="center"><font size="2" face="serif">May 31, 2005</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">4.73</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.98</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.84</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">3.13</font></td>
<td align="left">&nbsp;</td>
</tr>
</table>
<p align="left"><font size="2" face="serif">Crystallex has paid no dividends on its shares since incorporation and does not anticipate doing so in the foreseeable future.</font></p>
<p align="center"><font size="2" face="serif">9</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page> <a name="p10"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="center"><font size="2" face="serif">SHARE CAPITAL</font></p>
<p align="left"><font size="2" face="serif">As of June 24, 2005, Crystallex had 193,793,337 shares outstanding. None of the shares are held in treasury or by its subsidiaries.</font></p>
<p align="left"><font size="2" face="serif">As of June 24, 2005, Crystallex had outstanding options and warrants to acquire 20,598,985 common shares at exercise prices ranging from $0.80 to $3.75.</font></p>
<p align="left"><font size="2" face="serif">From January 1, 2001, through the date of this prospectus, Crystallex has issued the securities described below (in addition to common shares issued upon conversion of previously outstanding convertible securities, warrants, or options, and issues of common shares and stock options to consultants and management or directors): </font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $3,000,000 non-interest bearing notes, together with 450,000 common share purchase warrants.  Each warrant is exercisable for one Crystallex common share at exercise prices of $1.27 per share for 150,000 warrants and $1.316 per share for 300,000 warrants.  The non-interest bearing notes were exchanged for $3,000,000 principal amount of 4% convertible notes and 150,000 warrants to the holder and its affiliate, each warrant having an exercise price of $3.61.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $3,000,000 principal amount of 4% convertible notes and warrants to acquire 824,214 Crystallex common shares at an exercise price of $2.68 per share.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2,562,500
    special warrants at Cdn$1.60 per special warrant, each of which allow the
    holder to acquire, for no additional consideration, one common share and
    one-half (1/2) of one warrant to purchase common shares having an exercise
    price of Cdn$2.00 per each whole warrant.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2,400,000
    special warrants at Cdn$1.25 per special warrant, each of which allow the
    holder to acquire, for no additional consideration, one common share and
    one-half (1/2) of one warrant to purchase common shares having an exercise
    price of Cdn$1.60 per each whole warrant.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5,500,000
    special warrants at Cdn$1.25 per special warrant, each of which allow the
    holder to acquire, for no additional consideration, one common share and
    one-half (1/2) of one warrant to purchase common shares having an exercise
    price of Cdn$1.60 per each whole warrant.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 325,000 common shares to Vengroup as a settlement of distributions that Vengroup claimed relating to the El Callao properties. </font></p>
<p align="center"><font size="2" face="serif">10</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page> <a name="p11"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 52,500 special warrants at Cdn$3.02 per special warrant, each of which allow the holder to acquire one Crystallex common share without additional consideration.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $2,200,000 principal amount convertible note, convertible into up to Crystallex common shares based upon a discount to the shares&#8217; trading price at the time of conversion, and a warrant to purchase 100,000 common shares at an exercise price of Cdn$4.40 per common share.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2,200,000 special warrants for Cdn$3,025,780.  Each special warrant authorizes the holder to acquire one of Crystallex&#8217;s common shares for no additional consideration.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,025,000 special warrants purchased for $1,394,000, which special warrants may be converted, for no additional consideration, into 1,025,000 common shares and 1,025,000 common share purchase warrants having an exercise price of Cdn$2.75, together with an additional 13,750 common share purchase warrants to a selling agent.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8,195,025 common shares issued for El Callao Mining Corp shares and certain assets held by Bema Gold Corp in connection with Crystallex&#8217;s acquisition of El Callao.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3,111,111 units for a total purchase price of $4,725,000, each unit consisting of one Crystallex common share and one warrant to purchase one common share at an exercise price of Cdn$3.00.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4,545,455 special warrants, each of which allow the holder to acquire, for no additional consideration, one common share, and 2,272,727 share purchase warrants to purchase common shares having an exercise price of $2.75 per each warrant, for an aggregate sale price of $10,000,000.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Up to 5,000,000 common shares for issuance upon the conversion of 7% convertible notes and exercise of share warrants having an exercise price based upon a premium to the share price as of the date of issuance. </font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Up to 3,932,941 common shares upon the conversion of $950,000 Crystallex Series A 10% Redeemable Convertible Notes or the exercise of 190,000 common share purchase warrants having an exercise price of $1.09 per share, together with 67,059 common shares as a placement fee.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2,000,000 common shares or stock options to three consultants and to Crystallex&#8217;s counsel in Venezuela for services performed on Crystallex&#8217;s behalf.  </font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2,500,000 common shares in repayment of $2,500,000 principal amount of notes.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,336,743 common shares issued to Corporacion Vengroup S.A. in lieu of a $1,397,500 cash payment as the last installment of the purchase price for Crystallex&#8217;s indirect ownership of a majority interest in its El Callao property in Venezuela. </font></p>
<p align="center"><font size="2" face="serif">11</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page> <a name="p12"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12,800,000
    special warrants at $2.20 per special warrant, each of which allow the holder
    to acquire, for no additional consideration, and one common share, and one-half
    (1/2) of one warrant to purchase common shares having an exercise price of
    $2.75 per each whole warrant.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50,000 Crystallex common shares and 400,000 common share purchase warrants having an exercise price of Cdn$3.34 per share.  The shares and warrants were issued to an entity providing financial services to Crystallex.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 300,000 Crystallex common shares and 1,000,000 common share purchase warrants having an exercise price of $1.75 per share for the first 500,000 warrants (which vest immediately) and $2.00 per share for the second 500,000 warrants (which vest upon Crystallex receiving a project financing proposal acceptable to it).  The shares and warrants were issued to an entity providing financial services to Crystallex.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 28.75 million common shares at Cdn$4.00 per share for gross proceeds of Cdn$115 million, net proceeds of $82.0 million.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $100 million unit offering whereby Crystallex issued 100,000 units at a price of $1,000 per unit.  Each unit was comprised of $1,000 principal amount of senior unsecured notes, bearing interest of 9.375%, payable semi-annually and maturing on December 20, 2011, and 65 Crystallex common shares.  Net proceeds that Crystallex received, after underwriters&#8217; fees and related expenditures amounted to $95,500,000.</font></p>
<p align="center"><font size="2" face="serif">THE SECURITIES BEING OFFERED</font></p>
<p align="left"><font size="2" face="serif">Crystallex&#8217;s affiliates may
    use this prospectus to resell an aggregate of 8,117,250 common shares that
    they may receive upon exercise of options that Crystallex has granted to
    them
    through the date of this prospectus under the Incentive Share Option Plan
    (the &#8220;Option
    Plan&#8221;) or pursuant to written consulting or option agreements not subject
    to the Option Plan (collectively, the &#8220;Options&#8221;).  They may also
    use this prospectus, as it may be supplemented, to resell common shares that
    they receive upon exercise of options that Crystallex may grant to them under
    the Option Plan after the date of this prospectus. Crystallex adopted the
    Option Plan in 1997 and amended it in 1998, 2000, 2001, 2002, 2004, and 2005.
    As of the date of this prospectus, the Option Plan authorizes Crystallex
    to grant to its directors, officers, employees, or consultants options in
    an amount equal to up to 10% of Crystallex&#8217;s issued and outstanding
    shares. Crystallex has granted 14,144,458 options under the Option Plan as
    of the date of this prospectus and will likely grant additional options under
    the Option Plan.</font></p>
<p align="left"><font size="2" face="serif">Crystallex&#8217;s directors may
    also use this prospectus to resell up to an aggregate of 264,157 common shares
    that were issued or authorized for issuance through the date of this prospectus
    under the Directors Remuneration Plan and may also use this prospectus, as
    it may
    be
    supplemented,
    to resell common shares that they receive under that plan after the date
    of this prospectus. This resale prospectus involves only up to 600,000 shares
that were issued or may be issued under the Directors Remuneration Plan.</font></p>
<p align="center"><font size="2" face="serif">12</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page> <a name="p13"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="left"><font size="2" face="serif">Certain other selling shareholders
    may use this prospectus to resell up to an aggregate of 422,800 common shares
    that they received prior to the date of this prospectus upon their exercise,
    prior
to the date of this prospectus, of Options under the Option Plan.</font></p>
<p align="center"><font size="2" face="serif">USE OF PROCEEDS</font></p>
<p align="left"><font size="2" face="serif">Crystallex will not receive any of
    the proceeds from the sale of shares offered under this prospectus that were
    issued to directors under the Directors Remuneration Plan. Crystallex will
    receive approximately US$15.1 million in the aggregate if the selling shareholders
    fully exercise all of the 8,117,250 Crystallex Options issued to them but
    not yet exercised as of the date of this prospectus. The above amounts do
    not include shares issuable upon exercise of options by selling shareholders
    who are not Crystallex affiliates. Crystallex will not receive any sales
    proceeds when a selling shareholder sells his shares.</font></p>
<p align="center"><font size="2" face="serif">PLAN OF DISTRIBUTION</font></p>
<p align="left"><font size="2" face="serif">Crystallex is registering the resale of the common shares by the selling shareholders.  All costs, expenses and fees in connection with the registration of the common shares offered by this prospectus will be borne by Crystallex.  Brokerage commissions and similar selling expenses, if any, attributable to the sale of common shares will be borne by the selling shareholders.  Sales of common shares may be effected by the selling shareholders from time to time in one or more types of transactions (which may include block transactions) on the American Stock Exchange or The Toronto Stock Exchange or in the over-the-counter market, in negotiated transactions, through put or call options transactions relating to the common shares, through short sales of
common shares, or a combination of such methods of sale, at market prices prevailing at the time of sale, at negotiated prices, or at fixed prices, which may be changed.  These transactions may or may not involve brokers or dealers.</font></p>
<p align="left"><font size="2" face="serif">The selling shareholders may sell the shares directly to purchasers or to or through broker-dealers, which may act as agents or principals.  The broker-dealers may receive compensation in the form of discounts, concessions, or commissions from the selling shareholders and/or the purchasers of common shares for whom such broker-dealers may act as agents or to whom they sell as principal, or both (which compensation as to a particular broker-dealer might be in excess of customary commissions).</font></p>
<p align="left"><font size="2" face="serif">The selling shareholders and any broker-dealers that act in connections with the sale of common shares may be deemed to be &#8220;underwriters&#8221; within the meaning of Section 2(a)(11) of the Securities Act of 1933 and any commissions received by such broker-dealers and any profit on the resale of the common shares sold by them while acting as principals may be deemed to be underwriting discounts or commissions under the Securities Act.  The selling shareholders may agree to indemnify any agent, dealer or broker-dealer that participates in transactions involving sales of the common shares against certain liabilities, including liabilities arising under the Securities Act.</font></p>
<p align="center"><font size="2" face="serif">13</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page> <a name="p14"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="left"><font size="2" face="serif">Because the selling shareholders may be deemed to be &#8220;underwriters&#8221; within the meaning of Section 2(a)(11) of the Securities Act, they may be subject to the prospectus delivery requirements of the Securities Act, which may include delivery through the facilities of the American Stock Exchange under Rule 153 under the Securities Act.  Crystallex has informed the selling shareholders that the anti-manipulative provisions of Regulation M promulgated under the Securities Exchange Act may apply to its sales in the market.</font></p>
<p align="left"><font size="2" face="serif">Crystallex anticipates that the selling shareholders will offer for sale all of the common shares that they acquire.  <i>See</i> &#8220;The Securities Being Offered.&#8221;  Because it is possible that a significant number of common shares could be sold at one time under this prospectus, these sales, or the possibility of these sales, may have a depressive effect on the market price of Crystallex&#8217;s common shares.</font></p>
<p align="left"><font size="2" face="serif">To comply with the securities laws of certain jurisdictions, if applicable, the common shares will be offered or sold in those jurisdictions only through registered or licensed brokers or dealers.</font></p>
<p align="left"><font size="2" face="serif">Crystallex has agreed to pay all expenses of registering under the Securities Act and applicable state securities laws, if required, the shares that the selling shareholders may resell.  These expenses include, among others, SEC filing fees and expenses to comply with any applicable state securities or &#8220;blue sky&#8221; laws, printing expenses, and fees and disbursements of Crystallex&#8217;s counsel. However, the selling shareholders will pay all underwriting discounts and selling commissions, if any, that they may have in reselling the shares.</font></p>
<p align="left"><font size="2" face="serif">The following table sets forth Crystallex&#8217;s estimated expenses in connection with this offering:</font></p>
<table width="80%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif">Securities and Exchange Commission registration fee</font></td>
<td align="left" width="2%">&nbsp;</td>
<td width="1%" align="right"><font size="2" face="serif">$</font></td>
<td width="12%" align="right"><font size="2" face="serif">5,807</font></td>
<td width="2%" align="left">&nbsp;</td> </tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left"><font size="2" face="serif">Accountants' fees and expenses</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">5,000</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif">Legal fees and expenses</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">15,000</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left"><font size="2" face="serif">Printing and engraving expenses and copying expenses</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">     2,000</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif">Transfer agent&#8217;s fees and expenses</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">     2,000</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif">Miscellaneous</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">193</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top">
  <td></td>
  <td></td>
  <td><hr noshade size="1">
  </td>
  <td><hr noshade size="1">
  </td>
  <td></td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left"><div style="margin-left: 6%; text-indent: -3%"><font size="2" face="serif">Total</font></div></td>
<td align="left">&nbsp;</td>
<td align="right"><font size="2" face="serif"> $</font></td>
<td align="right"><font size="2" face="serif"> 30,000</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td></td>
<td></td>
<td><hr noshade size="2"></td>
<td><hr noshade size="2"></td>
<td></td>
</tr>
</table>
<p align="center"><font face="serif" size="2">14</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<a name="p15"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="center"><font size="2" face="serif">DESCRIPTION OF SECURITIES TO BE REGISTERED</font></p>
<p align="left"><font size="2" face="serif">Crystallex is authorized to issue an unlimited number of common shares without par value, an unlimited number of Class&nbsp;&#8220;A&#8221; preference shares and an unlimited number of Class&nbsp;&#8220;B&#8221; preference shares.  As at June 24, 2005, it had issued and outstanding 193,793,337 common shares, no Class&nbsp;&#8220;A&#8221; preference shares, and no Class &#8220;B&#8221; preference shares.  Each common share entitles the holder to dividends if, as and when declared by the directors, to one vote at all meetings of holders of common shares and to participate ratably in any distribution of Crystallex&#8217;s assets upon liquidation, dissolution or winding up, subject to the prior rights of holders of shares ranking in
priority to the common shares.</font></p>
<p align="left"><font size="2" face="serif"><i>See</i> &#8220;The Securities Being Offered&#8221; for a discussion of the options that Crystallex has issued or may issue and which are exercisable into common shares. </font></p>
<p align="center"><font size="2" face="serif">SELLING SHAREHOLDERS</font></p>
<p align="left"><font size="2" face="serif">Crystallex&#8217;s affiliates may use this prospectus to resell common shares that they receive upon exercise of options that Crystallex grants and issues to them prior to the date of this prospectus under the Incentive Share Option Plan and may also use this prospectus, as it may be supplemented, to resell common shares that they receive upon exercise of options that Crystallex grants and issues to them under that plan after the date of this prospectus.</font></p>
<p align="left"><font size="2" face="serif">Crystallex&#8217;s directors may use this prospectus to resell common shares that they received prior to the date of this prospectus under the Directors Remuneration Plan and may also use this prospectus, as it may be supplemented, to resell common shares that they receive under that plan after the date of this prospectus.</font></p>
<p align="left"><font size="2" face="serif">Certain persons named below may use this prospectus to resell common shares that they received upon their exercise, prior to the date of this prospectus, of options granted to them under the Share Option Plan. </font></p>
<p align="left"><font size="2" face="serif">In addition, the following table
    sets forth the name of each selling shareholder, his position(s), office(s),
    or other material relationship(s) with Crystallex or any of its affiliates
    during the past three years (or such shorter period as he may have been involved
    with Crystallex or the affiliate), and the number of shares: (i) each selling
    shareholder owned of record as of June 24, 2005 (assuming no exercise of
    options or warrants to acquire shares held by such person); (ii) that each
    selling
    shareholder is offering through this prospectus; and (iii) the percentage
    of all shares that each selling shareholder will own assuming that he sells
    all of the shares covered by this prospectus. Each selling shareholder may
    offer to sell some, all, or none of the shares that he offers pursuant to
    this prospectus. The percentages outstanding is based on 193,793,337 common
    shares outstanding as of June 24, 2005.</font></p>
<p align="left"><font size="2" face="serif">All information concerning beneficial ownership is to the best of Crystallex&#8217;s belief.  </font></p>
<p align="center"><font size="2" face="serif">15</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page> <a name="p16"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="left"><font size="2" face="serif"><b>[Numbers to be updated for issuances on June 24<sup>th</sup>]</b></font></p>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
<td align="left"><b><font size="1" face="serif">&nbsp;</font></b></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td colspan="4" align="center" valign="bottom"><b><font size="1" face="serif">Common Shares <br>
  Owned Before <br>
  Offering<sup>(1)</sup></font></b></td>
<td align="left" valign="bottom">&nbsp;</td>
<td align="right" valign="bottom">&nbsp;</td>
<td colspan="4" align="center" valign="bottom"><b><font size="1" face="serif">Common Shares <br>
  Offered in<br>
  Offering<sup>(1)</sup></font></b></td>
<td align="left" valign="bottom">&nbsp;</td>
<td align="right" valign="bottom">&nbsp;</td>
<td colspan="4" align="center" valign="bottom"><b><font size="1" face="serif">Common Shares <br>
  Owned After <br>
  Offering<sup>(1)</sup></font></b></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><b><font size="1" face="serif">Name and address of shareholder</font></b></td>
<td align="left" width="2%"><b><font size="1">&nbsp;</font></b></td>
<td width="1%" align="right"><b><font size="1">&nbsp;</font></b></td>
<td width="9%" align="center"><b><font size="1" face="serif">Number</font></b></td>
<td width="2%" align="left"><b><font size="1">&nbsp;</font></b></td>
<td width="1%" align="right"><b><font size="1">&nbsp;</font></b></td>
<td width="6%" align="center"><b><font size="1" face="serif">Percent</font></b></td>
<td width="2%" align="left"><b><font size="1">&nbsp;</font></b></td>
<td width="1%" align="right"><b><font size="1">&nbsp;</font></b></td>
<td width="9%" align="center"><b><font size="1" face="serif">Number</font></b></td>
<td width="2%" align="left"><b><font size="1">&nbsp;</font></b></td>
<td width="1%" align="right"><b><font size="1">&nbsp;</font></b></td>
<td width="5%" align="center"><b><font size="1" face="serif">Percent</font></b></td>
<td width="2%" align="left"><b><font size="1">&nbsp;</font></b></td>
<td width="1%" align="right"><b><font size="1">&nbsp;</font></b></td>
<td width="9%" align="center"><b><font size="1" face="serif">Number</font></b></td>
<td width="2%" align="left"><b><font size="1">&nbsp;</font></b></td>
<td width="1%" align="right"><b><font size="1">&nbsp;</font></b></td>
<td width="8%" align="center"><b><font size="1" face="serif">Percent</font></b></td>
<td width="2%" align="left">&nbsp;</td> </tr>
<tr valign="top">
<td><hr noshade size="1"></td>
<td></td>
<td><hr noshade size="1"></td>
<td><hr noshade size="1"></td>
<td></td>
<td><hr noshade size="1"></td>
<td><hr noshade size="1"></td>
<td></td>
<td><hr noshade size="1"></td>
<td><hr noshade size="1"></td>
<td></td>
<td><hr noshade size="1"></td>
<td><hr noshade size="1"></td>
<td></td>
<td><hr noshade size="1"></td>
<td><hr noshade size="1"></td>
<td></td>
<td><hr noshade size="1"></td>
<td><hr noshade size="1"></td>
<td></td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left"><font size="2" face="serif">Robert A. Fung<sup>(2), (3)</sup></font><br><font size="2" face="serif">Chairman and Director</font><br><font size="2" face="serif">49 Edenbrook Hill</font><br><font size="2" face="serif">Toronto, ON M9A 4A1</font><br><font size="2" face="serif">Canada</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">1,457,000</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="center"><font size="2" face="serif">*</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">1,457,000</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="center"><font size="2" face="serif">*</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">0</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">0</font></td>
<td align="left"><font size="2" face="serif">%</font></td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="center">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="center">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif">Todd Bruce<sup>(2)</sup></font><br><font size="2" face="serif">President and Director</font><br><font size="2" face="serif">25 Wentworth Court</font><br><font size="2" face="serif">Unionville, ON L3R 7N8</font><br><font size="2" face="serif">Canada</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">581,250</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="center"><font size="2" face="serif">*</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">581,250</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="center"><font size="2" face="serif">*</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">0</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">0</font></td>
<td align="left"><font size="2" face="serif">%</font></td>
</tr>
<tr valign="top" bgcolor="#ffffff">
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="center">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="center">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="center">&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left"><font size="2" face="serif">Marc J. Oppenheimer<sup>(2)</sup></font><br><font size="2" face="serif">Director, formerly President and CEO and Vice Chairman</font><br><font size="2" face="serif">466 Golf Course Drive</font><br><font size="2" face="serif">Leonia, NJ  07605</font><br><font size="2" face="serif">United States</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">2,689,685</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="center"><font size="2" face="serif">&#149;%</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">2,409,775</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="center"><font size="2" face="serif">1.37%</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">279,910</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">*</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="center">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="center">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif">Michael Brown<sup>(2)</sup></font><br><font size="2" face="serif">Director</font><br><font size="2" face="serif">40 Hillhurst Blvd.</font><br><font size="2" face="serif">Toronto, ON M5N 1N6</font><br><font size="2" face="serif">Canada</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">238,321</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="center"><font size="2" face="serif">*</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">238,321</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="center"><font size="2" face="serif">*</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">0</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">0</font></td>
<td align="left"><font size="2" face="serif">%</font></td>
</tr>
<tr valign="top" bgcolor="#ffffff">
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="center">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="center">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="center">&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left"><font size="2" face="serif">C. William Longden<sup>(2)</sup></font><br><font size="2" face="serif">Director</font><br><font size="2" face="serif">#32B-32 McMurrich Street</font><br><font size="2" face="serif">Toronto, ON M5R 2A2</font><br><font size="2" face="serif">Canada</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">442,389</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="center"><font size="2" face="serif">*</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">438,389</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="center"><font size="2" face="serif">*</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">4,000</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right" valign="top"><font size="2" face="serif">*</font></td>
<td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="center">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="center">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif">David I. Matheson<sup>(2), (4)</sup></font><br><font size="2" face="serif">Formerly, Director</font><br><font size="2" face="serif">201 Corleigh Blvd.</font><br><font size="2" face="serif">Toronto, ON M5N 1P6</font><br><font size="2" face="serif">Canada</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">368,040</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="center"><font size="2" face="serif">*</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">368,040</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="center"><font size="2" face="serif">*</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">0</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">0</font></td>
<td align="left"><font size="2" face="serif">%</font></td>
</tr>
<tr valign="top" bgcolor="#ffffff">
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="center">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="center">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left"><font size="2" face="serif">Harry J. Near<sup>(2)</sup></font><br><font size="2" face="serif">Director</font><br><font size="2" face="serif">551 Mariposa Avenue</font><br><font size="2" face="serif">Ottawa, ON K1M 0S5</font><br><font size="2" face="serif">Canada</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right" bgcolor="#FFFFFF"><font size="2" face="serif">966,229</font></td>
<td align="left" bgcolor="#FFFFFF">&nbsp;</td>
<td align="right" bgcolor="#FFFFFF">&nbsp;</td>
<td align="center" bgcolor="#FFFFFF"><font size="2" face="serif">*</font></td>
<td align="left" bgcolor="#FFFFFF">&nbsp;</td>
<td align="right" bgcolor="#FFFFFF">&nbsp;</td>
<td align="right" bgcolor="#FFFFFF"><font size="2" face="serif">996,229</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="center"><font size="2" face="serif">*</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">0</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">0</font></td>
<td align="left"><font size="2" face="serif">%</font></td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="center">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="center">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif">Armando F. Zullo<sup>(2)</sup></font><br><font size="2" face="serif">Director</font><br><font size="2" face="serif">1349 Mathers Avenue</font><br><font size="2" face="serif">W. Vancouver</font><br><font size="2" face="serif">British Columbia V7T 2G5</font><br><font size="2" face="serif">Canada</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">374,877</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="center"><font size="2" face="serif">*</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">374,877</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="center"><font size="2" face="serif">*</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">0</font></td>
<td align="left">&nbsp;</td>
<td align="right">&nbsp;</td>
<td align="right"><font size="2" face="serif">0</font></td>
<td align="left"><font size="2" face="serif">%</font></td>
</tr>
</table>
<p align="center"><font size="2" face="serif">16</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page> <a name="p17"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
  <tr valign="top" bgcolor="#ffffff">
    <td align="left"><font size="2" face="serif">Johan van&#8217;t Hof<sup>(2)</sup></font><br>
        <font size="2" face="serif">Director</font><br>
        <font size="2" face="serif">47 Golfdale Road</font><br>
        <font size="2" face="serif">Toronto, ON M4N 2B5</font><br>
        <font size="2" face="serif">Canada</font></td>
    <td width="2%" align="left">&nbsp;</td>
    <td width="1%" align="right">&nbsp;</td>
    <td width="9%" align="right"><font size="2" face="serif">214,775</font></td>
    <td width="2%" align="left">&nbsp;</td>
    <td width="1%" align="right">&nbsp;</td>
    <td width="6%" align="center"><font size="2" face="serif">*</font></td>
    <td width="2%" align="left">&nbsp;</td>
    <td width="1%" align="right">&nbsp;</td>
    <td width="9%" align="right"><font size="2" face="serif">214,775</font></td>
    <td width="2%" align="left">&nbsp;</td>
    <td width="1%" align="right">&nbsp;</td>
    <td width="5%" align="center"><font size="2" face="serif">*</font></td>
    <td width="2%" align="left">&nbsp;</td>
    <td width="1%" align="right">&nbsp;</td>
    <td width="9%" align="right"><font size="2" face="serif">0</font></td>
    <td width="2%" align="left">&nbsp;</td>
    <td width="1%" align="right">&nbsp;</td>
    <td width="8%" align="right"><font size="2" face="serif">0</font></td>
    <td width="2%" align="left"><font size="2" face="serif">%</font></td>
  </tr>
  <tr valign="top">
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top" bgcolor="#FFFFFF">
    <td align="left"><font size="2" face="serif">Daniel R. Ross<sup>(2)</sup></font><br>
        <font size="2" face="serif">Executive Vice President</font><br>
        <font size="2" face="serif">and Corporate Counsel,</font><br>
        <font size="2" face="serif">formerly, Director</font><br>
        <font size="2" face="serif">Unit 1030 </font><br>
        <font size="2" face="serif">400 Walmer Road</font><br>
        <font size="2" face="serif">Toronto, ON M5P 2X7</font><br>
        <font size="2" face="serif">Canada</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">868,751</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="center"><font size="2" face="serif">*</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">868,751</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="center"><font size="2" face="serif">*</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">0</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">0</font></td>
    <td align="left"><font size="2" face="serif">%</font></td>
  </tr>
  <tr valign="top">
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top" bgcolor="#ffffff">
    <td align="left"><font size="2" face="serif">Borden D. Rosiak<sup>(2)</sup></font><br>
        <font size="2" face="serif">Chief Financial Officer</font><br>
        <font size="2" face="serif">16 Swiftdale Place</font><br>
        <font size="2" face="serif">Toronto, ON M3B 1M4</font><br>
        <font size="2" face="serif">Canada</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">230,000</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="center"><font size="2" face="serif">*</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">230,000</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="center"><font size="2" face="serif">*</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">0</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">0</font></td>
    <td align="left"><font size="2" face="serif">%</font></td>
  </tr>
  <tr valign="top">
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top" bgcolor="#FFFFFF">
    <td align="left"><font size="2" face="serif">Kenneth Thomas<sup>(2)</sup></font><br>
        <font size="2" face="serif">Chief Operating Officer</font><br>
        <font size="2" face="serif">2005 Heartwood Court</font><br>
        <font size="2" face="serif">Mississauga, ON L5C 4P7</font><br>
        <font size="2" face="serif">Canada</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">130,000</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="center"><font size="2" face="serif">*</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">130,000</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="center"><font size="2" face="serif">*</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">0</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">0</font></td>
    <td align="left"><font size="2" face="serif">%</font></td>
  </tr>
  <tr valign="top">
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top" bgcolor="#ffffff">
    <td align="left"><font size="2" face="serif">Sadek El Alfy<sup>(2)</sup></font><br>
        <font size="2" face="serif">Vice President &#150; Operations</font><br>
        <font size="2" face="serif">P.O. Box 3368 </font><br>
        <font size="2" face="serif">Redmond, WA 98073</font><br>
        <font size="2" face="serif">United States</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">314,677</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="center"><font size="2" face="serif">*</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">282,000</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="center"><font size="2" face="serif">*</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">32,677</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">*</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top" bgcolor="#FFFFFF">
    <td align="left"><font size="2" face="serif">Dr. Luca Riccio</font><br>
        <font size="2" face="serif">Formerly, Vice President &#150; Explorations </font><br>
        <font size="2" face="serif">5403 Molina Road</font><br>
        <font size="2" face="serif">N. Vancouver, British Columbia</font><br>
        <font size="2" face="serif">V7R 4P5</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">218,000</font></td>
    <td align="left"><font size="2" face="serif"><sup>(2)</sup></font></td>
    <td align="right">&nbsp;</td>
    <td align="center"><font size="2" face="serif">*</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">3,000</font></td>
    <td align="left"><font size="2" face="serif"><sup>(5)</sup></font></td>
    <td align="right">&nbsp;</td>
    <td align="center"><font size="2" face="serif">*</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">215,000</font></td>
    <td align="left"><font size="2" face="serif"><sup>(2)</sup></font></td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">*</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top" bgcolor="#ffffff">
    <td align="left"><font size="2" face="serif">Richard Marshall</font><br>
        <font size="2" face="serif">Vice President &#150; Investor Relations </font><br>
        <font size="2" face="serif">515 Stonebrook Farms Drive</font><br>
        <font size="2" face="serif">Alpharetta, GA 30004</font><br>
        <font size="2" face="serif">United States</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">672,500</font></td>
    <td align="left"><font size="2" face="serif"><sup>(2)</sup></font></td>
    <td align="right">&nbsp;</td>
    <td align="center"><font size="2" face="serif">*</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">235,000</font></td>
    <td align="left"><font size="2" face="serif"><sup>(5)</sup></font></td>
    <td align="right">&nbsp;</td>
    <td align="center"><font size="2" face="serif">*</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">437,500</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">*</font></td>
    <td align="left">&nbsp;</td>
  </tr>
</table>
<p>&nbsp;</p>
<p align="center"><font size="2" face="serif">17</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page> <a name="p18"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
  <tr valign="top" bgcolor="#FFFFFF">
    <td align="left"><font size="2" face="serif">Maria Spencer Amaro</font><br>
        <font size="2" face="serif">Former employee</font><br>
        <font size="2" face="serif">333 Willow Street</font><br>
        <font size="2" face="serif">Apartment 102</font><br>
        <font size="2" face="serif">Teaneck, NJ 07666</font><br>
        <font size="2" face="serif">United States</font></td>
    <td width="2%" align="left">&nbsp;</td>
    <td width="1%" align="right">&nbsp;</td>
    <td width="9%" align="right"><font size="2" face="serif">2,800</font></td>
    <td width="2%" align="left"><font size="2" face="serif"><sup>(5)</sup></font></td>
    <td width="1%" align="right">&nbsp;</td>
    <td width="6%" align="center"><font size="2" face="serif">*</font></td>
    <td width="2%" align="left">&nbsp;</td>
    <td width="1%" align="right">&nbsp;</td>
    <td width="9%" align="right"><font size="2" face="serif">2,800</font></td>
    <td width="2%" align="left"><font size="2" face="serif"><sup>(5)</sup></font></td>
    <td width="1%" align="right">&nbsp;</td>
    <td width="5%" align="center"><font size="2" face="serif">*</font></td>
    <td width="2%" align="left">&nbsp;</td>
    <td width="1%" align="right">&nbsp;</td>
    <td width="9%" align="right"><font size="2" face="serif">0</font></td>
    <td width="2%" align="left">&nbsp;</td>
    <td width="1%" align="right">&nbsp;</td>
    <td width="8%" align="right"><font size="2" face="serif">0</font></td>
    <td width="2%" align="left"><font size="2" face="serif">%</font></td>
  </tr>
  <tr valign="top">
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top" bgcolor="#ffffff">
    <td align="left"><font size="2" face="serif">Andrea Maria Boltz</font><br>
        <font size="2" face="serif">Manager of Investor Relations</font><br>
        <font size="2" face="serif">2514 E. Montecito Avenue</font><br>
        <font size="2" face="serif">Phoenix, AZ 85016 </font><br>
        <font size="2" face="serif">United States</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">41,000</font></td>
    <td align="left"><font size="2" face="serif"><sup>(2)</sup></font></td>
    <td align="right">&nbsp;</td>
    <td align="center"><font size="2" face="serif">*</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">4,000</font></td>
    <td align="left"><font size="2" face="serif"><sup>(5)</sup></font></td>
    <td align="right">&nbsp;</td>
    <td align="center"><font size="2" face="serif">*</font></td>
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">37,000</font></td>
    <td align="left"><font size="2" face="serif"><sup>(2)</sup></font></td>
    <td align="right">&nbsp;</td>
    <td align="right"><font size="2" face="serif">*</font></td>
    <td align="left">&nbsp;</td>
  </tr>
</table>
<p align="left"><font size="2" face="serif">___</font><font size="2" face="serif">____</font></p>
<p align="left"><font size="2" face="serif">*  Less than 1%.</font></p>
<p align="left"><font size="2" face="serif"><sup>1  </sup>Assumes that the selling shareholders exercise all of their options into common shares.  (<i>See</i> &#8220;Securities Being Offered.&#8221;)  </font></p>
<p align="left"><font size="2" face="serif"><sup>2</sup>  Includes shares issuable upon the exercise of options.</font></p>
<p align="left"><font size="2" face="serif"><sup>3</sup>  Mr. Fung has also performed investment banking services for Crystallex.</font></p>
<p align="left"><font size="2" face="serif"><sup>4</sup>  Mr. Matheson is a member of McMillan Binch Mendelsohn LLP, counsel to Crystallex.  His term of office as a director expired on June 24, 2005.  <i>See </i>&#8220;Legal Matters.&#8221;</font></p>
<p align="left"><font size="2" face="serif"><sup>5</sup>  Does not include shares issuable upon the exercise of options.</font></p>
<p align="center"><font face="serif" size="2">18</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<a name="p19"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="center"><font size="2" face="serif">LEGAL MATTERS</font></p>
<p align="left"><font size="2" face="serif">Daniel R. Ross, Crystallex&#8217;s Executive
    Vice President and Corporate Counsel, has issued a legal opinion that the
    common shares offered under this prospectus, when issued as described herein,
    will
    be legally
    issued
    as fully
    paid and
    non-assessable shares in the capital of Crystallex. As of June 24, 2005,
    Mr. Ross owned less than one percent of the outstanding Crystallex comm shares.
    See &#8220;Selling Sharehodlers.&#8221; McMillan Binch Mendelsohn LLP has also advised
    Crystallex on matters set forth in &#8220;Enforceability of Civil Liabilities
    Against Crystallex.&#8221;  As
    of June 24, 2005, partners and associates of McMillan Binch Mendelsohn LLP
    owned, in the aggregate, less than one percent of the outstanding Crystallex
    common
    shares. See &#8220;Selling
Shareholders.&#8221; David I. Matheson, counsel to the firm, was a member of Crystallex&#8217;s
    Board of Directors until his term of office ended on June 24, 2005, and is
    also listed as a selling shareholder herein.  <i>See </i>&#8220;Selling
Shareholders.&#8221;</font></p>
<p align="center"><font size="2" face="serif">EXPERTS</font></p>
<p align="left"><font size="2" face="serif">The consolidated financial statements incorporated by reference in this prospectus from Crystallex International Corporation&#8217;s Annual Report on Form 40-F for the year ended December 31, 2004, have been audited by Deloitte &amp; Touche LLP, Independent Registered Chartered Accountants, as stated in their report, which is incorporated herein by reference, and has been so incorporated in reliance upon the report of such firm given upon their authority as experts in accounting and auditing.  Deloitte &amp; Touche LLP&#8217;s address is BCE Place, 181 Bay Street, Suite 1400, Toronto, Ontario  M5J 2V1, Canada.</font></p>
<p align="left"><font size="2" face="serif">This registration statement and prospectus contain one or more statements, reports, or other information attributed to each of the following persons as experts in the field of mining engineering:</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"></td>
<td width="3%">
<font size="2" face="serif">&#149;</font></td>
<td>
<font size="2" face="serif">Mine Development Associates, 210 South Rock Boulevard, Reno, Nevada  89502</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"></td>
<td width="3%">
<font size="2" face="serif">&#149;</font></td>
<td>
<font size="2" face="serif">Dr.&nbsp;Luca Riccio, P. Geo., 5403 Molina Rd., North Vancouver, BC, V7 4P5 Canada</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"></td>
<td width="3%">
<font size="2" face="serif">&#149;</font></td>
<td>
<font size="2" face="serif">SNC-Lavalin Engineers &amp; Constructors Inc., 2200 Lakeshore Blvd., Toronto, Ontario, Canada  M8V 1A4.</font></td>
</tr>
</table>
<p align="left"><font size="2" face="serif">The statements, reports, or other information from Mine Development Associates, Dr.&nbsp;Luca Riccio, P. Geo., and SNC-Lavalin Engineers &amp; Constructors Inc. which are attributed to any of these experts are used in this registration statement and prospectus with the consent of each of these experts to which these statements, reports, or other information are attributed.</font></p>
<p align="center"><font size="2" face="serif"><i>[Remainder of page intentionally blank]</i></font></p>
<p align="center">&nbsp;</p>
<p align="center">&nbsp;</p>
<p align="center">&nbsp;</p>
<p align="center">&nbsp;</p>
<p align="center">&nbsp;</p>
<p align="center"><font face="serif" size="2">19</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<a name="pii1"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="center"><font size="2" face="serif"><b>PART II</b></font></p>
<p align="center"><font size="2" face="serif"><b>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</b></font></p>
<p align="left"><font size="2" face="serif"><b>Item 3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incorporation of Documents by Reference.</b></font></p>
<p align="left"><font size="2" face="serif">The following documents filed by Crystallex International Corporation are incorporated by reference into this Registration Statement:</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Crystallex's Annual Report on Form 40-F and on Form 40-F/A &#150; No. 1 for the fiscal year ended December 31, 2004, filed under Section 13 of the Securities Exchange Act.</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The description of Crystallex's common shares without par value contained in Crystallex&#8217;s registration statement under Section 12(b) of the Securities Exchange Act on Form 8-A (Registration No. 1-14620). </font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Crystallex&#8217;s registration statement under Section 12(b) of the Securities Exchange Act on Form 8-A of rights to acquire Crystallex&#8217;s common shares (Registration No. 1-14620).  </font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Report of Foreign Issuer on Form 6-K furnished to the SEC on April 1, 2005, on May 12, 2005, on May 13, 2005, on May 20, 2005, on June 22, 2005,<b></b>and on June 24, 2005.  Crystallex&#8217;s report on Form 6-K furnished on May 12, 2005, contains its unaudited financial statements for the quarter ended March 31, 2005.</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All subsequent annual reports filed by Crystallex on Form 20-F, Form 40-F, or Form 10-K, and all subsequent filings on Forms 10-Q and 8-K filed by Crystallex under Sections 12, 13, 14 or 15(d) of the Securities Exchange Act, after the date of this prospectus and before the termination of the offering are deemed incorporated by reference into and be a part of this prospectus from the date of filing such documents.</font></td>
</tr>
</table>
<p align="left"><font size="2" face="serif">Crystallex may incorporate by reference into this prospectus any Form 6-K that it furnishes to the SEC under Sections 12, 13, 14 or 15(d) of the Securities Exchange Act after the date of this prospectus and before the offering is completed, and make that Form 6-K a part of this prospectus from the date it files the form, but only to the extent that Crystallex identifies in the Form 6-K that it is being incorporated by reference into this prospectus. </font></p>
<p align="left"><font size="2" face="serif">Crystallex will provide to each person, including any beneficial owner, to whom a prospectus is delivered, a copy of any or all of the information that Crystallex incorporates by reference in this prospectus but is not delivered with the prospectus, free of charge by contacting Crystallex&#8217;s Secretary, Daniel R. Ross, orally or in writing, at our principal offices, which are located at 18 King Street East, Suite 1210, Toronto, Ontario, M5C 1C4, telephone number (416) 203-2448, or by contacting investor relations at <u>info@crystallex.com</u>.  However, Crystallex will not provide a copy of exhibits to items that it incorporates by reference unless it specifically incorporates those exhibits by reference.</font></p>
<p align="center">&nbsp;</p>
<p align="center"><font size="2" face="serif">II-1</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page> <a name="pii2"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="left"><font size="2" face="serif"><b>Item 4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Description of Securities.</b></font></p>
<p align="left"><font size="2" face="serif">Not applicable.</font></p>
<p align="left"><font size="2" face="serif"><b>Item 5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interests of Named Experts and Counsel.</b></font></p>
<p align="left"><font size="2" face="serif">McMillan Binch Mendelsohn LLP has issued a legal opinion that the common shares offered under this prospectus, when issued as described herein, will be legally issued as fully paid and non-assessable shares in the capital of Crystallex and has also advised Crystallex on matters set forth in &#8220;Enforceability of Civil Liabilities Against Crystallex.&#8221;  As of May 1, 2005, partners and associates of McMillan Binch Mendelsohn LLP owned, in the aggregate, less than one percent of the outstanding Crystallex common shares.  David I. Matheson, counsel to the firm, was a member of Crystallex&#8217;s Board of Directors until his term of office ended on June 24, 2005, and is also listed as a selling shareholder herein.   <i>See </i>&#8220;Selling
Shareholder.&#8221;</font></p>
<p align="left"><font size="2" face="serif"><b>Item 6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers.</b></font></p>
<p align="left"><font size="2" face="serif">Under the Canadian Business Corporation Act (&#8220;CBCA&#8221;), in exercising their powers and performing their functions, each member of Crystallex&#8217;s Board of Directors is required to act honestly and in good faith and with a view to the best interests of Crystallex.  Under the CBCA, Crystallex has broad power to indemnify, and under certain circumstances is required to indemnify, its directors and officers against liabilities that they may incur while serving as directors or officers of Crystallex, including liabilities arising under the Securities Act, provided that they acted honestly and in good faith with a view to the best interests of Crystallex, and, in the case of a criminal or administrative action or proceeding that is
enforced by a monetary penalty, they had reasonable grounds for believing the conduct was lawful.  </font></p>
<p align="left"><font size="2" face="serif">In addition, Crystallex has agreed to indemnify each of Crystallex&#8217;s directors against any liabilities arising from his actions in his capacity with Crystallex, provided that he acted honestly and in good faith with a view to the best interests of Crystallex and, in the case of a criminal or administrative act or proceeding that is enforced by a monetary penalty, he had reasonable grounds for believing that his conduct was lawful.  Crystallex maintains directors and officers liability insurance.  Crystallex has also agreed to indemnify Marc J. Oppenheimer (at the time of such agreement, Crystallex&#8217;s President, Chief Executive Officer, and a director, and, since September 2003, a Crystallex director) against any liabilities arising
from his acting in his capacity with Crystallex to the fullest extent permitted under the Business Corporation Act of New Jersey (the state where Mr. Oppenheimer resides) or the laws of Canada. </font></p>
<p align="left"><font size="2" face="serif">Crystallex also maintains an insurance policy for directors and officers insuring them against certain liabilities incurred by them in the performances of their duties, including liabilities under the Securities Act.</font></p>
<p align="center"><font size="2" face="serif">II-2</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page> <a name="pii3"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="left"><font size="2" face="serif">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, Crystallex has been advised that in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.  In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of Crystallex in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being
registered, Crystallex will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</font></p>
<p align="left"><font size="2" face="serif"><b>Item 7.  Exemption from Registration Claimed.</b></font></p>
<p align="left"><font size="2" face="serif">The restricted securities to be reoffered or resold pursuant to this registration statement were issued to Crystallex&#8217;s then chief executive officer registrant, to the executive assistant to Crystallex&#8217;s then-chief executive officer as of the date of the grant of options, to Crystallex&#8217;s Vice President &#150; Exploration and to its Vice President &#150; Investor Relations, and to its Manager of Investor Relations, pursuant to Section 4(2) of and Rule 506 under the Securities Act of 1933, as amended.</font></p>
<p align="left"><font size="2" face="serif"><b>Item 8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.</b></font></p>
<p align="left"><font size="2" face="serif">The following are filed herewith as part of this Registration Statement:</font></p>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top" bgcolor="#FFFFFF">
<td width="10%" align="left"><font size="2" face="serif"><b><u>Exhibit No.</u></b></font></td>
<td width="3%" align="right">&nbsp;</td>
<td width="66%" align="left"><font size="2" face="serif"><b><u>Exhibit</u></b></font></td>
</tr>
<tr valign="top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left"><font size="2" face="serif">5</font></td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">Opinion of Daniel R. Ross as to the legality of the securities being registered</font></td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif">23.1</font></td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">Consent of Deloitte &amp; Touche LLP</font></td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left"><font size="2" face="serif">23.2</font></td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">The consent of Daniel R. Ross is included in its opinion filed herewith as Exhibit 5</font></td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif">23.3<sup>(1)</sup></font></td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">Consent of Mine Development Associates</font></td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left"><font size="2" face="serif">23.4<sup>(2)</sup></font></td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">Consent of Dr. Luca Riccio</font></td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif">23.5</font></td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">Consent of SNC-Lavalin Engineers &amp; Constructors Inc.</font></td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
</tr>
<tr valign="top" bgcolor="#ffffff">
  <td align="left"><font size="2" face="serif">23.6</font></td>
  <td align="right">&nbsp;</td>
  <td align="left"><font size="2" face="serif">Consent of McMillan Binch Mendelsohn
    LLP</font></td>
</tr>
<tr valign="top" bgcolor="#ffffff">
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top" bgcolor="#ffffff">
<td align="left"><font size="2" face="serif">24</font></td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">Power of Attorney (contained as part of the Signature Pages)</font></td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="right">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
</tr>
</table>
<p align="center"><font size="2" face="serif">II-3</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page> <a name="pii4"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
  <tr valign="top" bgcolor="#FFFFFF">
    <td width="10%" align="left"><font size="2" face="serif">99.1</font></td>
    <td width="3%" align="right">&nbsp;</td>
    <td width="66%" align="left"><font size="2" face="serif">Incentive Share Option Plan,
        as amended in 2005 (subject to shareholder approval)</font></td>
  </tr>
  <tr valign="top">
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
  </tr>
  <tr valign="top" bgcolor="#ffffff">
    <td align="left"><font size="2" face="serif">99.2</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">Directors Remuneration Plan,
        as amended and restated as of January 1, 2005</font></td>
  </tr>
  <tr valign="top">
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
  </tr>
  <tr valign="top" bgcolor="#FFFFFF">
    <td align="left"><font size="2" face="serif">99.3</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">Share Option Agreement dated
        as of November 10, 1997, between the Registrant and Robert J. Fung, together
        with Option Amending Agreement dated as of December 21, 1998, between
        the Registrant and Mr. Fung and
        schedule
        of
        substantially
        similar agreements between the Registrant and Harry J. Near and the Registrant
        and Daniel R. Ross</font></td>
  </tr>
  <tr valign="top">
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
  </tr>
  <tr valign="top" bgcolor="#ffffff">
    <td align="left"><font size="2" face="serif">99.4</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">Share Option Agreement dated
        as of March 10, 1997, between the Registrant and Marc J. Oppenheimer,
        together with
        Option
        Amending
        Agreement
        dated as of December 21, 1998, between the Registrant and Mr. Oppenheimer</font></td>
  </tr>
  <tr valign="top">
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
  </tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td colspan="2"><font size="2" face="serif">___</font><font size="2" face="serif">____</font></td>
  </tr>
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">(1)</font></td>
<td align="left">
<font size="2" face="serif"> Filed as Exhibit 23.3 with Pre-Effective Amendment No. 1 to Registration Statement No. 333-13838, filed on October 19, 2001.</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">(2)</font></td>
<td align="left">
<font size="2" face="serif"> Filed as Exhibit 23.4 with Annual Report on Form 40-F for the year ended December 31, 2004, filed on March 31, 2004.</font></td>
</tr>
</table>
<p align="left"><font size="2" face="serif"><b>Item 9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Undertakings.</b></font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
  <tr valign="top">
    <td width="3%"><font size="2" face="serif">&nbsp;(a)</font></td>
    <td align="left"><font size="2" face="serif">The undersigned registrant hereby
    undertakes:</font></td>
  </tr>
  <tr valign="top">
    <td>&nbsp;</td>
    <td align="left">&nbsp;</td>
  </tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td><font size="2" face="serif">(1)</font></td>
  <td align="left"><font size="2" face="serif">To file, during any period in
      which offers or sales are being made, a post-effective amendment to this
    Registration Statement:</font></td>
</tr>
<tr valign="top">
  <td>&nbsp;</td>
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)  To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent
no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement;</font></td>
</tr>
</table>
<p>&nbsp;</p>
<p align="center"><font size="2" face="serif">II-4</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page> <a name="pii5"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<i>Provided, however</i>, That paragraphs (a)1(i) and (a)(1)(ii) of this section do not apply if the registration statement is on Form S-3, Form S-8 or Form F-3, and the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement.</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">
<font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">&nbsp;</font></td>
<td align="left">
<font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</font></td>
</tr>
</table>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</font></p>
<p align="center"><font size="2" face="serif">II-5</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<a name="pii7"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="center"><font size="2" face="serif"><b>SIGNATURES</b></font></p>
<p align="left"><font size="2" face="serif">Pursuant to the requirements of the
    Securities Act of 1933, the registrant certifies that it has reasonable grounds
    to believe that it meets all of the requirements for filing on Form S-8 and
    has duly caused this Registration Statement to be signed on its behalf by
    the undersigned, thereunto duly authorized, in the City of Toronto, Province
    of Ontario, Canada, on this 24<sup>th</sup> day of June, 2005.</font></p>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td width="30%">&nbsp;</td>
    <td colspan="2"><font size="2" face="serif">CRYSTALLEX INTERNATIONAL CORPORATION</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td width="10%">&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font size="2" face="serif">By: <u>/s/ Todd Bruce</u></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font size="2" face="serif"><i>Todd Bruce<br>
    </i><b>President, Principal Executive Officer and Director</b><i>    </i></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font size="2" face="serif"><b>Date: </b> June 24, 2005</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font size="2" face="serif">By: <font size="2" face="serif"><u>/s/ <font size="2" face="serif">Marc
    J. Oppenheimer</font></u></font></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font size="2" face="serif"><i>Marc J. Oppenheimer<br>
    </i><b>Director</b><i> <br>
    </i><b>and Authorized Representative in the United States</b><i>    </i></font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><font size="2" face="serif"><b>Date: </b>June 24, 2005</font></td>
  </tr>
</table>
<p>&nbsp;</p>
<p align="center"><font size="2" face="serif">POWER OF ATTORNEY</font></p>
<p align="left"><font size="2" face="serif">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Todd Bruce or Marc J. Oppenheimer, or any one of them, his or her attorney-in-fact, with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Registration Statement on Form S-8, and to file same, with exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact, or his or her substitute or substitutes, may do or cause to be done by virtue hereof.</font></p>
<p align="left"><font size="2" face="serif">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.</font></p>
<p align="center"><font size="2" face="serif"><i>[signatures begin on next page]</i></font></p>
<p align="center">&nbsp;</p>
<p align="center"><font size="2" face="serif">II-6</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page> <a name="pii8"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td align="left" width="39%"><font size="2" face="serif"><u>Signature</u></font></td>
<td align="left" width="3%">&nbsp;</td>
<td align="left" width="42%"><font size="2" face="serif"><u>Title</u></font></td>
<td align="left"><font size="2" face="serif"><u>Date</u></font></td>
</tr>
<tr valign="top">
<td></td>
<td></td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">/s/ Robert A. Fung</font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">Chairman and Director</font></td>
<td align="left"><font size="2" face="serif">June 24, 2005</font></td>
</tr>
<tr valign="top">
<td align="left"><hr size="1" noshade><font size="2" face="serif"><b>Robert A. Fung</b></font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
</tr>
<tr valign="top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td> </tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">/s/ Todd Bruce</font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">President, Principal</font></td>
<td align="left"><font size="2" face="serif">June 24, 2005</font></td>
</tr>
<tr valign="top">
<td align="left"><hr size="1" noshade></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">Executive Officer and</font></td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">&nbsp;<b>Todd Bruce</b></font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">Director</font></td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
</tr>
<tr valign="top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td> </tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">/s/ Marc J. Oppenheimer</font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">Director</font></td>
<td align="left"><font size="2" face="serif">June 24, 2005</font></td>
</tr>
<tr valign="top">
<td align="left"><hr size="1" noshade><font size="2" face="serif"><b>Marc J. Oppenheimer</b></font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
</tr>
<tr valign="top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td> </tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">/s/ Michael Brown</font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">Director</font></td>
<td align="left"><font size="2" face="serif">June 24, 2005</font></td>
</tr>
<tr valign="top">
<td align="left"><hr size="1" noshade><font size="2" face="serif"><b>Michael Brown</b></font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
</tr>
<tr valign="top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td> </tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">/s/ C. William Longden</font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">Director</font></td>
<td align="left"><font size="2" face="serif">June 24, 2005</font></td>
</tr>
<tr valign="top">
<td align="left"><hr size="1" noshade><font size="2" face="serif"><b>C. William Longden</b></font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
</tr>
<tr valign="top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td> </tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">/s/ Harry J. Near</font></td>
<td align="left"></td>
<td align="left"><font size="2" face="serif">Director</font></td>
<td align="left"><font size="2" face="serif">June 24, 2005</font></td>
</tr>
<tr valign="top">
<td align="left"><hr size="1" noshade><font size="2" face="serif"><b>Harry J. Near</b></font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
</tr>
<tr valign="top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td> </tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">/s/ Armando F. Zullo</font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">Director</font></td>
<td align="left"><font size="2" face="serif">June 24, 2005</font></td>
</tr>
<tr valign="top">
<td align="left"><hr size="1" noshade><font size="2" face="serif"><b>Armando F. Zullo</b></font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
</tr>
<tr valign="top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td> </tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">/s/ Johan C. Van&#8217;t Hof</font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">Director</font></td>
<td align="left"><font size="2" face="serif">June 24, 2005</font></td>
</tr>
<tr valign="top">
<td align="left"><hr size="1" noshade><font size="2" face="serif"><b>Johan C. Van&#8217;t Hof</b></font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
</tr>
<tr valign="top">
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td> </tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">/s/ Borden D. Rosiak</font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">Principal Financial Officer</font></td>
<td align="left"><font size="2" face="serif">June 24, 2005</font></td>
</tr>
<tr valign="top">
<td align="left"><hr size="1" noshade><font size="2" face="serif"><b>Borden D. Rosiak</b></font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">and Principal Accounting Officer</font></td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
</tr>
</table>
<p align="center"><font face="serif" size="2">II-7</font></p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<a name="pii9"></a>
<p><a href="#contents"><font size="2">Back to Contents</font></a></p>
<p align="center"><font size="2" face="serif"><b>EXHIBIT INDEX</b></font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following exhibits are filed herewith as part of this Registration Statement:</font></p>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
  <tr valign="top" bgcolor="#FFFFFF">
    <td width="10%" align="left"><font size="2" face="serif"><b><u>Exhibit No.</u></b></font></td>
    <td width="3%" align="right">&nbsp;</td>
    <td width="66%" align="left"><font size="2" face="serif"><b><u>Exhibit</u></b></font></td>
    <td width="2%" align="left">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td></td>
  </tr>
  <tr valign="top" bgcolor="#ffffff">
    <td align="left"><font size="2" face="serif">5</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">Opinion of Daniel R. Ross as to the legality of the securities being registered</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top" bgcolor="#FFFFFF">
    <td align="left"><font size="2" face="serif">23.1</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">Consent of Deloitte &amp; Touche
        LLP</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top" bgcolor="#ffffff">
    <td align="left"><font size="2" face="serif">23.2</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">The consent of Daniel R. Ross is included in its opinion filed herewith as Exhibit 5</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top" bgcolor="#FFFFFF">
    <td align="left"><font size="2" face="serif">23.3<sup>(1)</sup></font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">Consent of Mine Development
        Associates</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top" bgcolor="#ffffff">
    <td align="left"><font size="2" face="serif">23.4<sup>(2)</sup></font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">Consent of Dr. Luca Riccio</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top" bgcolor="#FFFFFF">
    <td align="left"><font size="2" face="serif">23.5</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">Consent of SNC-Lavalin Engineers &amp; Constructors
        Inc.</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top" bgcolor="#ffffff">
    <td align="left"><font size="2" face="serif">23.6</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">Consent of McMillan Binch Mendelsohn, LLP</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top" bgcolor="#ffffff">
    <td align="left">&nbsp;</td>
    <td align="right">&nbsp;</td>
    <td align="left">&nbsp;</td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top" bgcolor="#ffffff">
    <td align="left"><font size="2" face="serif">24</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">Power of Attorney (contained
        as part of the Signature Pages)</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top" bgcolor="#FFFFFF">
    <td align="left"><font size="2" face="serif">99.1</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">Incentive Share Option Plan,
        as amended in 2005 (subject to shareholder approval)</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top" bgcolor="#ffffff">
    <td align="left"><font size="2" face="serif">99.2</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">Directors Remuneration Plan,
        as amended and restated as of January 1, 2005</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top" bgcolor="#FFFFFF">
    <td align="left"><font size="2" face="serif">99.3</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">Share Option Agreement dated
        as of November 10, 1997, between the Registrant and Robert J. Fung, together
        with Option Amending Agreement dated as of December
        21, 1998, between the Registrant and Mr. Fung and schedule of substantially
        similar agreements between the Registrant and Harry J. Near and the Registrant
        and Daniel R. Ross</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top" bgcolor="#ffffff">
    <td align="left"><font size="2" face="serif">99.4</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">Share Option Agreement dated
        as of March 10, 1997, between the
        Registrant and Marc J. Oppenheimer, together with Option Amending Agreement
        dated as of December 21, 1998, between the Registrant and Mr. Oppenheimer</font></td>
    <td align="left">&nbsp;</td>
  </tr>
  <tr valign="top">
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="right">&nbsp;</td>
    <td align="left"><font size="2" face="serif">&nbsp;</font></td>
    <td align="left">&nbsp;</td>
  </tr>
</table>
<p align="left"><font size="2" face="serif">_____</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"><font size="2" face="serif">(1)</font></td>
<td align="left">
<font size="2" face="serif"> Filed as Exhibit 23.3 with Pre-Effective Amendment No. 1 to Registration Statement No. 333-13838, filed on October 19, 2001.</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><font size="2" face="serif">(2)</font></td>
<td align="left">
<font size="2" face="serif"> Filed as Exhibit 23.4 with Annual Report on Form 40-F for the year ended December 31, 2004, filed on March 31, 2004.</font></td>
</tr>
</table>
<p align="center"><font face="serif" size="2">II-8</font></p>
<hr noshade align="center" width="100%" size="2">
</body>
</html>
[{"type": "S-8", "sequence": "1", "filename": "b407207_s8.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 191813}]
{"company-data": {"conformed-name": "CRYSTALLEX INTERNATIONAL CORP", "cik": "0000912500", "assigned-sic": "1040", "irs-number": "000000000", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-126128", "film-number": "05915812"}, "business-address": {"street1": "18 KING STREET EAST", "street2": "SUITE 1210", "city": "TORONTO", "state": "A6", "zip": "M5C 1C4", "phone": "4162032448"}, "mail-address": {"street1": "18 KING STREET EAST", "street2": "SUITE 1210", "city": "TORONTO", "state": "A6", "zip": "M5C 1C4"}}
Prepared and filed by St Ives Financial
As filed with the Securities and Exchange Commission on June 24, 2005
Registration No. 333-•
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER  THE SECURITIES ACT OF 1933
CRYSTALLEX INTERNATIONAL CORPORATION
(Exact name of registrant as specified in its charter)
Canada
98-0152628
(State or
    other jurisdiction of
incorporation or organization)
(I.R.S.
    Employer
Identification No.)
18 King Street East, Suite 1210,
      Toronto, Ontario, Canada M5C 1C4
(Address of principal executive offices) (zip code)
Incentive Share Option Plan,
      Share Option Agreements, and
Directors Remuneration Plan
(Full title of plans)
Corporation Service Company
1090 Vermont Avenue, N.W., Suite 430
Washington, D.C. 20005
(Name and address of agent for service)
(888) 690-2882
(Telephone number, including area code, of agent for service)
Copy to:
Lawrence W. Koltun, Esq.
Koltun & King, P.C.
1146 19th Street, N.W., Suite 250
Washington, D.C. 20036
This registration statement contains a resale prospectus, pursuant to General Instruction C thereof, relating to both this registration statement as well as Registrations No. 333-7568, 333-9876, and 333-12890.
Back to Contents
CALCULATION OF REGISTRATION FEE
Title of securities to
be registered
Amount to be
registered
Proposed maximum
offering price
per share (1)
Proposed
maximum
aggregate
offering price (1)
Amount of
fee (1)
Options to acquire common
shares without par value (1)
16,279,500
Options
Common shares without par
value
    issuable upon exercise of
stock options
    (2)
6,779,500
common shares
$
(3
)
$
14,943,355
$
4,503.55
(4)
Common shares without par
value
    issuable upon exercise of
stock
Options
    (5)
2,000,000 common shares
$
(3
)
$
2,655,735
$
701.11
(6)
Common shares without par
value
    issuable upon exercise of
stock Options (7)
13,263,162
common shares
$
3.72 (7)
$
49,338,962 (7)
$
5,807.20
(8)
Common shares without par
value (9)
600,000
common shares
$
(3
)
$
320,086
$
88.98
(10)
Total
22,642,662
common shares
$
(3
)
$
67,258,138
$
11,100.84
(4), (6), (8), (10)
(1)
Consisting of options to purchase common shares under the registrant's Incentive Share Option Plan adopted in 1997, as amended in 1998, 2000, 2001, 2002, 2004, and 2005.  There is no fee associated with the options to be registered, as the common shares underlying the options are being registered herein.
(2)
Includes common shares, and options to acquire such shares, previously registered under Registrations Nos. 333-7568 and 333-9876.  Pursuant to Rule 416 under the Securities Act of 1933, the number of shares also includes shares issuable pursuant to antidilution provisions relating to the securities that are convertible or exercisable into common shares being registered hereby.  The registrant is using a resale prospectus for both such registration statements pursuant to Rule 429.
(3)
The determination of the proposed maximum offering prices per share is set forth in Registrations Nos. 333-7568, 333-9876, and 333-12890.
ii
Back to Contents
(4)
The registrant paid $4,228.75 in filing fees upon filing Registration No. 333-7568 and an additional $274.80 in filing fees upon filing Registration No. 333-9876.
(5)
Includes common shares, and options to acquire such shares, previously registered under Registration No. 333-12890.  Pursuant to Rule 416 under the Securities Act of 1933, the number of shares also includes shares issuable pursuant to antidilution provisions relating to the securities that are convertible or exercisable into common shares being registered hereby.  The registrant is using a resale prospectus for such registration statement pursuant to Rule 429.
(6)
The registrant paid $701.11 in filing fees in connection with such shares upon filing Registration No. 333-12890.
(7)
The offering price for the 7,689,458 shares is determined pursuant to Rule 457(c) and (h) based upon the average of the high and low prices reported for the registrant's common shares on the American Stock Exchange as of June 22, 2005. Pursuant to Rule 416 under the Securities Act of 1933, the number of shares also includes shares issuable pursuant to antidilution provisions relating to the securities that are convertible or exercisable into common shares being registered hereby. The registrant is using a resale prospectus for such shares pursuant to Rule 429.
(8)
Paid herewith.
(9)
Includes common shares previously registered in Registration No. 333-12890 under the registrant's Directors Remuneration Plan.  The registrant is using a resale prospectus for such registration statement pursuant to Rule 429.
(10)
The registrant paid $88.98 in filing fees in connection with such shares upon filing Registration No. 333-12890.
iii
Back to Contents
PART I
The information specified by Part
    I of Form S-8 has been omitted from this Registration Statement on Form S-8
    with respect to offers and sales of up to 8,381,407 common shares without
    par value
(the "Shares") of Crystallex International Corporation pursuant to
its Incentive Share Option Plan (the "Option Plan"), consulting or
option agreements not subject to such plan, and the Directors Remuneration Plan
(the "Directors Plan") referred to herein.  The document will be
sent or given to the Option Plan's and Directors Plan's participants
and the persons subject to such consulting or option agreements.
In accordance with General Instruction
    C to Form S-8 as promulgated by the Securities and Exchange Commission, Crystallex
    has prepared this resale prospectus with respect to offers and sales of its
    Shares by its affiliates pursuant to the Option Plan. This prospectus also
    covers the offers and sales by Crystallex affiliates or non-affiliates of
    up to 422,800 restricted Shares issued upon their exercise, prior to the
    date of this prospectus, of options issued pursuant to the Option Plan, and
    the
    offers and sales of unregistered Shares acquired prior to the date of this
prospectus by Crystallex affiliates pursuant to the Directors Plan.
This prospectus has been prepared in accordance with the requirements of General Instruction C to Form S-8 and Part I of Form F-3.
iv
Back to Contents
CRYSTALLEX INTERNATIONAL CORPORATION
Organized under the Laws of Canada
RESALE PROSPECTUS
8,804,207 Common Shares
Certain selling shareholders who
    are affiliates of Crystallex International Corporation may use this prospectus
    to sell their Crystallex common shares that they may acquire when they exercise
    stock options to acquire up to an aggregate of 7,274,750 common shares that
    Crystallex has granted or may grant to them under its Incentive Share Option
    Plan adopted in 1997 (as modified in 1998, 2000, 2001, 2002, 2004, and 2005)
    and up to 842,500 common shares that Crystallex may issue pursuant to written
    consulting options or agreements not subject to such plan (collectively,
    the "Options").  In addition, certain selling shareholders who
    are Crystallex directors may use this prospectus to sell periodically up
    to an aggregate of 264,157 common shares that Crystallex issued or authorized
    for issuance to them pursuant to Crystallex's Directors Remuneration
    Plan. Furthermore, certain selling shareholders, some of whom are not Crystallex
    affiliates,
    may use
    this prospectus to resell 422,800 Crystallex common shares that they
    received upon the exercise of Options prior to the date of this prospectus.
See
"Selling
    Shareholders."  Crystallex will not receive any sales proceeds when
    a selling shareholder sells his shares.
The selling shareholders may sell all or any portion of these Crystallex common shares in one or more transactions through ordinary brokerage transactions, in private, negotiated transactions, or through any other means described in the section entitled "Plan of Distribution" beginning on page 13.
The sales may be made at market prices prevailing at the time of sale, at negotiated prices, or at fixed prices, which may be changed.  These transactions may or may not involve brokers or dealers.  Crystallex will not receive any sales proceeds when these selling shareholders convert their convertible notes or convertible debentures or sell their common shares, but Crystallex will receive the exercise price of any warrants that the
selling shareholders exercise.
Crystallex lists the common shares
    for trading on The American Stock Exchange and on The Toronto Stock Exchange
    under the symbol KRY. As of June 23, 2005, the closing price for the common
    shares on The American Stock Exchange was US$3.72 and on The Toronto Stock
    Exchange
was Cdn$4.65.
It may be risky to purchase the common shares.  See "Risk Factors" beginning on page 4.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus.  Any representation to the contrary is a criminal offense.
*               *               *
The date of this prospectus is June 24, 2005.
Back to Contents
TABLE OF CONTENTS
Item
Page
SUMMARY OF CRYSTALLEX
3
RISK FACTORS
4
HOW TO OBTAIN MORE INFORMATION
5
ENFORCEABILITY OF
    CIVIL LIABILITIES AGAINST CRYSTALLEX
7
FORWARD-LOOKING STATEMENTS
7
CAPITALIZATION AND INDEBTEDNESS
8
RECENT DEVELOPMENTS
8
RECENT PRICE HISTORY
9
SHARE CAPITAL
10
THE SECURITIES BEING OFFERED
12
USE OF PROCEEDS
13
PLAN OF DISTRIBUTION
13
DESCRIPTION OF SECURITIES TO BE
    REGISTERED
15
SELLING SHAREHOLDERS
15
LEGAL MATTERS
19
EXPERTS
19
2
Back to Contents
You should rely only on the information contained in this prospectus and the information incorporated into this prospectus by reference (
see
"Incorporation of Documents by Reference") and not upon anything else in deciding whether to purchase the common shares offered through this prospectus.  Neither Crystallex nor any of the selling shareholders will authorize providing you with any other information in connection with your purchase.  This prospectus does not offer to sell or solicit an offer to buy any security other than the common shares that this prospectus offers.  In addition, this prospectus does not offer to sell or solicit any offer to buy any common shares to any person in any jurisdiction where it is unlawful to
make this offer to or solicit an offer from a person in that jurisdiction.
Note:
Unless otherwise indicated, all amounts in this prospectus are stated in U.S. dollars.
SUMMARY OF CRYSTALLEX
Crystallex was incorporated on May 22, 1984 under the Company Act of the province of British Columbia, Canada.  On January 23, 1998, its corporate existence was continued under the Canada Business Corporation Act ("CBCA"), thereby bringing Crystallex under the jurisdiction of the CBCA as if it was originally incorporated under the CBCA.  Crystallex trades as a public company on the TSX and the AMEX under the symbol "KRY".  It engages in exploring, developing, and mining for gold, with its primary focus in Venezuela, and in evaluating mineral property acquisitions in various locations around the world.  Crystallex is currently producing gold from the Tomi concession in Venezuela and processing ore from the Tomi concession
at Crystallex's Revemin Mill in Venezuela. Crystallex also has rights to extract ore from its La Victoria mine in Venezuela and is pursuing permits to develop an underground mine at its Albino 1 concession in the Kilometre 88 region of Venezuela.  Crystallex also has secured rights to develop the gold deposits known as Las Cristinas 4, 5, 6 and 7, also in the Kilometre 88 region.
Property
Location
Percentage Interest,
Direct or Indirect
Las Cristinas
Venezuela
100
%
(1)
Tomi
Venezuela
100
%
Revemin Mill
Venezuela
93
%
Albino 1
Venezuela
100
%
(2)
Lo Increible
Venezuela
51
%
(3)
(1)
Refers to an agreement granted to Crystallex to mine the property.
See
"Risk Factors" in Crystallex's Form 40-F for the year ended December 31, 2004.
(2)
In early 2005, Crystallex was informed that its concession rights for Albino 1 have been rescinded.  Crystallex is appealing this rescission.
See "
Risk Factors" in Crystallex's Form 40-F for the year ended December 31, 2004.
(3)
Crystallex owns 100% of El Callao Mining Corp., which indirectly owns 51% of the Lo Increible property.
3
Back to Contents
Details with respect to all of the foregoing properties are provided in the documents incorporated by reference.
See
"How to Obtain More Information."
Crystallex's principal executive office, registered office, and principal place of business are located at 18 King Street East, Suite 1210, Toronto, Ontario, M5C 1C4, telephone number (416) 203-2448.
RISK FACTORS
Your purchase of the common shares may be risky.  In addition to the other information contained in this prospectus or incorporated by reference into this prospectus, please read carefully the risk factors contained in Crystallex's Annual Report on Form 40-F for its Fiscal Year Ended December 31, 2004, together with the following factors, before purchasing common shares offered by this prospectus:
Crystallex has incurred recent losses.
Crystallex incurred net losses in
    2004, 2003, 2002, and 2001. Crystallex's profitability depends, among
    other things, on the price of gold, the level of gold production, cash operating
    costs and other factors discussed in "Risk Factors."  Substantially
    all of these factors are beyond Crystallex's control.
As part
    of the preparation of its financial statements for the year ended December
    31, 2004, Crystallex undertook a detailed review of the carrying value of
    each of its mineral properties as well as related deferred exploration costs
    and its plant and equipment. Based on this review, and reflecting the impact
    of its recently received notice of the termination of its Albino 1 concession,
    Crystallex incurred a write-down of $32 million for the year ended December
    31, 2004. The write-down included $10.5 million for Albino, $13.8 million
    for Revemin, $3.6 million for Tomi, and $4.1 million for other properties.
Crystallex has authorized for issuance a large number of shares, which, if issued in significant amounts, could result in dilution of share ownership and a reduction in share price.
As at June 24, 2005, Crystallex has
    authorized the issuance of more than 20.6 million common shares
    that have not yet been issued for payment of certain property purchases and
    related indebtedness, the exercise of stock options, finder's fees, the exercise
    of warrants issued in private placements, placement agent's fees for a private
    placement, and exercise of warrants issued for convertible notes and broker's
    fees. Furthermore, Crystallex may issue additional common shares from time
    to time in the future. If Crystallex issues a substantial number of those
    new shares, it could substantially dilute the ownership interest of Crystallex's
    current shareholders, based upon the 193,793,337 Crystallex shares outstanding
    as of June 24,
2005. In addition, given Crystallex's average daily trading volume
of approximately 617,200 shares on the American Stock Exchange ("AMEX")
(Consolidated Market) and approximately 597,000 shares on the Toronto Stock Exchange
("TSX") for the period January 1, 2004 through December 31, 2004,
the sale of these shares could provide enough selling pressure to depress the
share price of Crystallex's common shares.
4
Back to Contents
HOW TO OBTAIN MORE INFORMATION
We file reports and other information
    with the Securities and Exchange Commission. You may read any document we
    file at the SEC's public reference rooms at 450 Fifth Street, N.W.
    in Washington, D.C. 20549. Please call the SEC toll free at 1-800-SEC-0330
    for information about its public reference rooms. The SEC maintains an Internet
    site,
http://www.sec.gov,
that contains reports, proxy and information
    statements, and other information regarding issuers that file electronically
    with the SEC. A copy of our SEC filings since October, 2002, including a
    copy of this prospectus, the registration statement (and amendments to the
    registration statement) relating to this prospectus and our annual report
    on Form 40-F and Form 40-F/A-No. 1 for our year ended December 31, 2004,
    our Forms 6-K submitted to the SEC since November 4, 2002, all amendments
    to
    any of
    these
    filings
    or reports, and all future documents or reports that we will file or submit
    to the SEC, are or will be also available to you free of charge at the SEC's
    Internet site.
We have filed with the SEC a registration statement on Form S-8 under the Securities Act of 1933 relating to this prospectus. This prospectus does not contain all of the information in the registration statement.  We have omitted certain parts of the registration statement, as permitted by the rules and regulations of the SEC.  You may inspect and copy the registration statement, including exhibits, at the SEC's public reference facilities.  Our statements in this prospectus are not necessarily complete about the contents of any contract or other document. You should refer to the copy of each contract or other document we have filed as an exhibit to the registration statement for complete information.
The SEC allows us to "incorporate by reference" into this prospectus information we file with the SEC. This means that we can disclose important information to you by referring you to those documents. This information we incorporate by reference is considered a part of this prospectus, and later information we file with the SEC will automatically update and supersede this information. We incorporate by reference the documents listed below and any future filings we make with the SEC under Sections 12, 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934 until this offering is completed:
(a)     Crystallex's
    Annual Report on Form 40-F and on Form 40-F/A – No. 1 for the fiscal
    year ended December 31, 2004, filed under Section 13 of the Securities Exchange
    Act.
(b)     The
    description of Crystallex's common shares without par value contained in
    Crystallex's registration statement under Section 12(b) of the Securities
    Exchange Act on Form 8-A (Registration No. 1-14620).
(c)     Crystallex's
    registration statement under Section 12(b) of the Securities Exchange Act
    on Form 8-A of rights to acquire Crystallex's common shares (Registration
    No. 1-14620).
5
Back to Contents
(d)    The
    Report of Foreign Issuer on Form 6-K furnished to the SEC on April 1, 2005,
    on May 12, 2005, on May 13, 2005, on May 20, 2005, on June 22, 2005,
and
    on June 24, 2005. Crystallex's report on Form 6-K furnished on May
    12, 2005, contains its unaudited financial statements for the quarter ended
    March 31, 2005.
(e)     All
    subsequent annual reports filed by Crystallex on Form 20-F, Form 40-F, or
    Form 10-K, and all subsequent filings on Forms 10-Q and 8-K filed by Crystallex
    under Sections 12, 13, 14 or 15(d) of the Securities Exchange Act, after
    the date of this prospectus and before the termination of the offering are
    deemed incorporated by reference into and be a part of this prospectus from
    the date of filing such documents.
Crystallex may incorporate by reference into this prospectus any Form 6-K that it furnishes to the SEC under Sections 12, 13, 14 or 15(d) of the Securities Exchange Act after the date of this prospectus and before the offering is completed, and make that Form 6-K a part of this prospectus from the date it files the form, but only to the extent that Crystallex identifies in the Form 6-K that it is being incorporated by reference into this prospectus.
Crystallex will provide to each person, including any beneficial owner, to whom a prospectus is delivered, a copy of any or all of the information that Crystallex incorporates by reference in this prospectus but is not delivered with the prospectus, free of charge by contacting Crystallex's Secretary, Daniel R. Ross, orally or in writing, at our principal offices, which are located at 18 King Street East, Suite 1210, Toronto, Ontario, M5C 1C4, telephone number (416) 203-2448, or by contacting investor relations at
info@crystallex.com
.  However, Crystallex will not provide a copy of exhibits to items that it incorporates by reference unless it specifically incorporates those exhibits by reference.
You should rely only on the information provided in this prospectus or any prospectus supplement. We have not authorized anyone else to provide you with different information. The selling shareholders are not making an offer of these securities in any state or other jurisdiction where the offer is not permitted. This prospectus does not offer to you any security other than the common shares that this prospectus specifically offers.  Information contained on our Web site is not a part of this prospectus.
6
Back to Contents
ENFORCEABILITY OF CIVIL LIABILITIES AGAINST CRYSTALLEX
The enforcement by purchasers of the common shares offered in this prospectus of civil liabilities under the federal securities laws of the United States may be adversely affected by the fact that Crystallex is a Canadian corporation, many of its directors and shareholders are residents of Canada, and the majority of Crystallex's assets and all or a substantial portion of the assets of such other persons are located outside the United States.  As a result, it may be difficult for purchasers to effect service of process within the United States upon such persons or to realize against them in the United States upon judgments of courts of the United States predicated upon civil liabilities under securities laws of the United States.  McMillan
Binch Mendelsohn LLP, Canadian counsel for Crystallex, advised Crystallex that there is doubt as to the enforceability in Canada against Crystallex or its directors or officers who are not residents of the United States in original actions or in actions for enforcement of judgments of United States courts of liabilities predicated upon federal securities laws of the United States.
FORWARD-LOOKING STATEMENTS
All statements other than statements of historical fact included in this prospectus regarding Crystallex's financial position, business strategy and plans and objectives of management of Crystallex for future operations, are forward-looking statements.  When used in this prospectus, words such as "anticipate," "believe," "estimate," "expect," "intend," "will," "could," "may" and similar expressions, as they relate to Crystallex or its management, identify forward-looking statements.  These forward-looking statements are based on the beliefs of Crystallex's management, as well as assumptions made by and information currently available to
Crystallex's management.  Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as those disclosed under "Risk Factors" in this prospectus, including but not limited to, competitive factors and pricing pressures, changes in legal and regulatory requirements, technological change or difficulties, product development risks, commercialization and trade difficulties and general economic conditions.  Such statements reflect the current views of Crystallex with respect to future events and are subject to these and other risks, uncertainties and assumptions relating to the operations, results of operations, and growth strategy of Crystallex.  All subsequent written and oral forward-looking statements
attributable to Crystallex or persons acting on its behalf are expressly qualified in their entirety by this paragraph.
[text continues on next page]
7
Back to Contents
CAPITALIZATION AND INDEBTEDNESS
As of April 30, 2005
(unaudited)
Notes and Debentures
Actual
As Adjusted(1)
Debt
Current
    portion of long-term debt
$
4,258,470
$
4,258,470
Total
    long-term debt, net of current portion
79,210,959
79,210,959
Total
    Debt
$
83,469,429
$
83,469,429
Stockholders' equity
Common
    shares (unlimited shares authorized; 192,631,619 issued and outstanding)
311,855,538
311,855,538
Contributed Surplus
30,649,009
30,649,009
Cumulative Translation Adjustment
11,958,981
11,958,981
Deficit
(218,474,832
)
(218,474,832
)
Total stockholders' equity
$
135,988,696
$
135,988,696
Total Capitalization
$
219,458,125
$
219,458,125
_______
(1)
Does not include the exercise into Crystallex common shares of any options, special warrants, or warrants outstanding as of April 30, 2005, or that may be issued thereafter.
RECENT DEVELOPMENTS
Prior to 2004, Crystallex issued approximately 800,000 common shares to Standard Bank of London ("SBL") as partial settlement of its outstanding loan with SBL. Crystallex and SBL also entered into an agreement whereby SBL agreed not to sell the Crystallex shares it had obtained as the loan repayment in large blocks but instead disposed of the shares in an orderly fashion over time (Orderly Disposition Agreement or "ODA").
As provided by the ODA, on final disposition of the shares issued to SBL, SBL would retain any aggregate sale proceeds in excess of the issue price of the shares and certain agreed interest (excess proceeds) and apply the excess proceeds against any obligations owing to SBL by Crystallex, whereas any final aggregate shortfall would require payment by Crystallex to SBL to cover the shortfall. The excess proceeds or shortfall could only be determined and applied when all shares subject to the ODA had been disposed.
SBL sold the last block of the shares by the end of May 2004.  It had cumulative excess proceeds from sale of all of the shares of approximately $4 million.  Crystallex and SBL agreed to allocate the excess proceeds against outstanding commodity contract obligations that Crystallex had with SBL.  Crystallex accounted for the allocation of proceeds against outstanding commodity contract obligations as a reduction of its commodity contract loss (that is, an income statement item) in its June 30, 2004, and September 30, 2004, unaudited interim financial statements.  Crystallex disclosed this accounting in the notes to the financial statements for both periods.
8
Back to Contents
However, in preparing its full year financial statements for its year ended December 31, 2004, Crystallex accounted for this transaction as an increase in its share capital rather than an income statement item.  Crystallex reflected this accounting treatment in it year-end 2004 audited financial statement and in its disclosure of its quarterly financial information contained in its year-end Management's Discussion and Analysis ("MD&A").  Both the year-end audited financial statements and MD&A are contained in exhibits attached to Crystallex's Annual Report on Form 40-F.
See
"How To Obtain More Information."
RECENT PRICE HISTORY
Crystallex's common shares trade on the TSX and on the AMEX under stock symbol "KRY".  The discussion contained in this section is based upon information provided by the Toronto Stock Exchange or American Stock Exchange, as applicable.  The following tables presents additional closing price information:
Toronto Stock Exchange
CDN $
American Stock Exchange
US$
High
Low
High
Low
Fiscal Quarter Ended
March 31, 2003
2.44
1.25
1.55
0.85
June 30, 2003
2.86
1.00
2.15
0.69
September 30, 2003
4.48
2.01
3.25
1.38
December 31, 2003
4.15
2.90
3.20
2.17
March 31, 2004
5.00
3.15
3.75
2.36
June 30, 2004
4.12
2.75
3.14
1.99
September 30, 2004
4.21
2.70
3.37
2.05
December 31, 2004
5.41
3.82
4.52
3.02
March 31, 2005
5.00
3.80
3.99
3.05
Months Ended
December 31, 2004
4.50
4.05
3.76
3.30
January 31, 2005
4.28
3.83
3.51
3.11
February 28, 2005
4.45
3.80
3.63
3.05
March 31, 2005
5.00
4.08
3.99
3.28
April 30, 2005
5.17
4.35
4.19
3.57
May 31, 2005
4.73
3.98
3.84
3.13
Crystallex has paid no dividends on its shares since incorporation and does not anticipate doing so in the foreseeable future.
9
Back to Contents
SHARE CAPITAL
As of June 24, 2005, Crystallex had 193,793,337 shares outstanding. None of the shares are held in treasury or by its subsidiaries.
As of June 24, 2005, Crystallex had outstanding options and warrants to acquire 20,598,985 common shares at exercise prices ranging from $0.80 to $3.75.
From January 1, 2001, through the date of this prospectus, Crystallex has issued the securities described below (in addition to common shares issued upon conversion of previously outstanding convertible securities, warrants, or options, and issues of common shares and stock options to consultants and management or directors):
•      $3,000,000 non-interest bearing notes, together with 450,000 common share purchase warrants.  Each warrant is exercisable for one Crystallex common share at exercise prices of $1.27 per share for 150,000 warrants and $1.316 per share for 300,000 warrants.  The non-interest bearing notes were exchanged for $3,000,000 principal amount of 4% convertible notes and 150,000 warrants to the holder and its affiliate, each warrant having an exercise price of $3.61.
•      $3,000,000 principal amount of 4% convertible notes and warrants to acquire 824,214 Crystallex common shares at an exercise price of $2.68 per share.
•      2,562,500
    special warrants at Cdn$1.60 per special warrant, each of which allow the
    holder to acquire, for no additional consideration, one common share and
    one-half (1/2) of one warrant to purchase common shares having an exercise
    price of Cdn$2.00 per each whole warrant.
•      2,400,000
    special warrants at Cdn$1.25 per special warrant, each of which allow the
    holder to acquire, for no additional consideration, one common share and
    one-half (1/2) of one warrant to purchase common shares having an exercise
    price of Cdn$1.60 per each whole warrant.
•      5,500,000
    special warrants at Cdn$1.25 per special warrant, each of which allow the
    holder to acquire, for no additional consideration, one common share and
    one-half (1/2) of one warrant to purchase common shares having an exercise
    price of Cdn$1.60 per each whole warrant.
•      325,000 common shares to Vengroup as a settlement of distributions that Vengroup claimed relating to the El Callao properties.
10
Back to Contents
•      52,500 special warrants at Cdn$3.02 per special warrant, each of which allow the holder to acquire one Crystallex common share without additional consideration.
•      $2,200,000 principal amount convertible note, convertible into up to Crystallex common shares based upon a discount to the shares' trading price at the time of conversion, and a warrant to purchase 100,000 common shares at an exercise price of Cdn$4.40 per common share.
•      2,200,000 special warrants for Cdn$3,025,780.  Each special warrant authorizes the holder to acquire one of Crystallex's common shares for no additional consideration.
•      1,025,000 special warrants purchased for $1,394,000, which special warrants may be converted, for no additional consideration, into 1,025,000 common shares and 1,025,000 common share purchase warrants having an exercise price of Cdn$2.75, together with an additional 13,750 common share purchase warrants to a selling agent.
•      8,195,025 common shares issued for El Callao Mining Corp shares and certain assets held by Bema Gold Corp in connection with Crystallex's acquisition of El Callao.
•      3,111,111 units for a total purchase price of $4,725,000, each unit consisting of one Crystallex common share and one warrant to purchase one common share at an exercise price of Cdn$3.00.
•      4,545,455 special warrants, each of which allow the holder to acquire, for no additional consideration, one common share, and 2,272,727 share purchase warrants to purchase common shares having an exercise price of $2.75 per each warrant, for an aggregate sale price of $10,000,000.
•      Up to 5,000,000 common shares for issuance upon the conversion of 7% convertible notes and exercise of share warrants having an exercise price based upon a premium to the share price as of the date of issuance.
•      Up to 3,932,941 common shares upon the conversion of $950,000 Crystallex Series A 10% Redeemable Convertible Notes or the exercise of 190,000 common share purchase warrants having an exercise price of $1.09 per share, together with 67,059 common shares as a placement fee.
•      2,000,000 common shares or stock options to three consultants and to Crystallex's counsel in Venezuela for services performed on Crystallex's behalf.
•      2,500,000 common shares in repayment of $2,500,000 principal amount of notes.
•      1,336,743 common shares issued to Corporacion Vengroup S.A. in lieu of a $1,397,500 cash payment as the last installment of the purchase price for Crystallex's indirect ownership of a majority interest in its El Callao property in Venezuela.
11
Back to Contents
•      12,800,000
    special warrants at $2.20 per special warrant, each of which allow the holder
    to acquire, for no additional consideration, and one common share, and one-half
    (1/2) of one warrant to purchase common shares having an exercise price of
    $2.75 per each whole warrant.
•      50,000 Crystallex common shares and 400,000 common share purchase warrants having an exercise price of Cdn$3.34 per share.  The shares and warrants were issued to an entity providing financial services to Crystallex.
•      300,000 Crystallex common shares and 1,000,000 common share purchase warrants having an exercise price of $1.75 per share for the first 500,000 warrants (which vest immediately) and $2.00 per share for the second 500,000 warrants (which vest upon Crystallex receiving a project financing proposal acceptable to it).  The shares and warrants were issued to an entity providing financial services to Crystallex.
•      28.75 million common shares at Cdn$4.00 per share for gross proceeds of Cdn$115 million, net proceeds of $82.0 million.
•      $100 million unit offering whereby Crystallex issued 100,000 units at a price of $1,000 per unit.  Each unit was comprised of $1,000 principal amount of senior unsecured notes, bearing interest of 9.375%, payable semi-annually and maturing on December 20, 2011, and 65 Crystallex common shares.  Net proceeds that Crystallex received, after underwriters' fees and related expenditures amounted to $95,500,000.
THE SECURITIES BEING OFFERED
Crystallex's affiliates may
    use this prospectus to resell an aggregate of 8,117,250 common shares that
    they may receive upon exercise of options that Crystallex has granted to
    them
    through the date of this prospectus under the Incentive Share Option Plan
    (the "Option
    Plan") or pursuant to written consulting or option agreements not subject
    to the Option Plan (collectively, the "Options").  They may also
    use this prospectus, as it may be supplemented, to resell common shares that
    they receive upon exercise of options that Crystallex may grant to them under
    the Option Plan after the date of this prospectus. Crystallex adopted the
    Option Plan in 1997 and amended it in 1998, 2000, 2001, 2002, 2004, and 2005.
    As of the date of this prospectus, the Option Plan authorizes Crystallex
    to grant to its directors, officers, employees, or consultants options in
    an amount equal to up to 10% of Crystallex's issued and outstanding
    shares. Crystallex has granted 14,144,458 options under the Option Plan as
    of the date of this prospectus and will likely grant additional options under
    the Option Plan.
Crystallex's directors may
    also use this prospectus to resell up to an aggregate of 264,157 common shares
    that were issued or authorized for issuance through the date of this prospectus
    under the Directors Remuneration Plan and may also use this prospectus, as
    it may
    be
    supplemented,
    to resell common shares that they receive under that plan after the date
    of this prospectus. This resale prospectus involves only up to 600,000 shares
that were issued or may be issued under the Directors Remuneration Plan.
12
Back to Contents
Certain other selling shareholders
    may use this prospectus to resell up to an aggregate of 422,800 common shares
    that they received prior to the date of this prospectus upon their exercise,
    prior
to the date of this prospectus, of Options under the Option Plan.
USE OF PROCEEDS
Crystallex will not receive any of
    the proceeds from the sale of shares offered under this prospectus that were
    issued to directors under the Directors Remuneration Plan. Crystallex will
    receive approximately US$15.1 million in the aggregate if the selling shareholders
    fully exercise all of the 8,117,250 Crystallex Options issued to them but
    not yet exercised as of the date of this prospectus. The above amounts do
    not include shares issuable upon exercise of options by selling shareholders
    who are not Crystallex affiliates. Crystallex will not receive any sales
    proceeds when a selling shareholder sells his shares.
PLAN OF DISTRIBUTION
Crystallex is registering the resale of the common shares by the selling shareholders.  All costs, expenses and fees in connection with the registration of the common shares offered by this prospectus will be borne by Crystallex.  Brokerage commissions and similar selling expenses, if any, attributable to the sale of common shares will be borne by the selling shareholders.  Sales of common shares may be effected by the selling shareholders from time to time in one or more types of transactions (which may include block transactions) on the American Stock Exchange or The Toronto Stock Exchange or in the over-the-counter market, in negotiated transactions, through put or call options transactions relating to the common shares, through short sales of
common shares, or a combination of such methods of sale, at market prices prevailing at the time of sale, at negotiated prices, or at fixed prices, which may be changed.  These transactions may or may not involve brokers or dealers.
The selling shareholders may sell the shares directly to purchasers or to or through broker-dealers, which may act as agents or principals.  The broker-dealers may receive compensation in the form of discounts, concessions, or commissions from the selling shareholders and/or the purchasers of common shares for whom such broker-dealers may act as agents or to whom they sell as principal, or both (which compensation as to a particular broker-dealer might be in excess of customary commissions).
The selling shareholders and any broker-dealers that act in connections with the sale of common shares may be deemed to be "underwriters" within the meaning of Section 2(a)(11) of the Securities Act of 1933 and any commissions received by such broker-dealers and any profit on the resale of the common shares sold by them while acting as principals may be deemed to be underwriting discounts or commissions under the Securities Act.  The selling shareholders may agree to indemnify any agent, dealer or broker-dealer that participates in transactions involving sales of the common shares against certain liabilities, including liabilities arising under the Securities Act.
13
Back to Contents
Because the selling shareholders may be deemed to be "underwriters" within the meaning of Section 2(a)(11) of the Securities Act, they may be subject to the prospectus delivery requirements of the Securities Act, which may include delivery through the facilities of the American Stock Exchange under Rule 153 under the Securities Act.  Crystallex has informed the selling shareholders that the anti-manipulative provisions of Regulation M promulgated under the Securities Exchange Act may apply to its sales in the market.
Crystallex anticipates that the selling shareholders will offer for sale all of the common shares that they acquire.
See
"The Securities Being Offered."  Because it is possible that a significant number of common shares could be sold at one time under this prospectus, these sales, or the possibility of these sales, may have a depressive effect on the market price of Crystallex's common shares.
To comply with the securities laws of certain jurisdictions, if applicable, the common shares will be offered or sold in those jurisdictions only through registered or licensed brokers or dealers.
Crystallex has agreed to pay all expenses of registering under the Securities Act and applicable state securities laws, if required, the shares that the selling shareholders may resell.  These expenses include, among others, SEC filing fees and expenses to comply with any applicable state securities or "blue sky" laws, printing expenses, and fees and disbursements of Crystallex's counsel. However, the selling shareholders will pay all underwriting discounts and selling commissions, if any, that they may have in reselling the shares.
The following table sets forth Crystallex's estimated expenses in connection with this offering:
Securities and Exchange Commission registration fee
$
5,807
Accountants' fees and expenses
5,000
Legal fees and expenses
15,000
Printing and engraving expenses and copying expenses
2,000
Transfer agent's fees and expenses
2,000
Miscellaneous
193
Total
$
30,000
14
Back to Contents
DESCRIPTION OF SECURITIES TO BE REGISTERED
Crystallex is authorized to issue an unlimited number of common shares without par value, an unlimited number of Class "A" preference shares and an unlimited number of Class "B" preference shares.  As at June 24, 2005, it had issued and outstanding 193,793,337 common shares, no Class "A" preference shares, and no Class "B" preference shares.  Each common share entitles the holder to dividends if, as and when declared by the directors, to one vote at all meetings of holders of common shares and to participate ratably in any distribution of Crystallex's assets upon liquidation, dissolution or winding up, subject to the prior rights of holders of shares ranking in
priority to the common shares.
See
"The Securities Being Offered" for a discussion of the options that Crystallex has issued or may issue and which are exercisable into common shares.
SELLING SHAREHOLDERS
Crystallex's affiliates may use this prospectus to resell common shares that they receive upon exercise of options that Crystallex grants and issues to them prior to the date of this prospectus under the Incentive Share Option Plan and may also use this prospectus, as it may be supplemented, to resell common shares that they receive upon exercise of options that Crystallex grants and issues to them under that plan after the date of this prospectus.
Crystallex's directors may use this prospectus to resell common shares that they received prior to the date of this prospectus under the Directors Remuneration Plan and may also use this prospectus, as it may be supplemented, to resell common shares that they receive under that plan after the date of this prospectus.
Certain persons named below may use this prospectus to resell common shares that they received upon their exercise, prior to the date of this prospectus, of options granted to them under the Share Option Plan.
In addition, the following table
    sets forth the name of each selling shareholder, his position(s), office(s),
    or other material relationship(s) with Crystallex or any of its affiliates
    during the past three years (or such shorter period as he may have been involved
    with Crystallex or the affiliate), and the number of shares: (i) each selling
    shareholder owned of record as of June 24, 2005 (assuming no exercise of
    options or warrants to acquire shares held by such person); (ii) that each
    selling
    shareholder is offering through this prospectus; and (iii) the percentage
    of all shares that each selling shareholder will own assuming that he sells
    all of the shares covered by this prospectus. Each selling shareholder may
    offer to sell some, all, or none of the shares that he offers pursuant to
    this prospectus. The percentages outstanding is based on 193,793,337 common
    shares outstanding as of June 24, 2005.
All information concerning beneficial ownership is to the best of Crystallex's belief.
15
Back to Contents
[Numbers to be updated for issuances on June 24
th
]
Common Shares
Owned Before
Offering
(1)
Common Shares
Offered in
Offering
(1)
Common Shares
Owned After
Offering
(1)
Name and address of shareholder
Number
Percent
Number
Percent
Number
Percent
Robert A. Fung
(2), (3)
Chairman and Director
49 Edenbrook Hill
Toronto, ON M9A 4A1
Canada
1,457,000
*
1,457,000
*
0
0
%
Todd Bruce
(2)
President and Director
25 Wentworth Court
Unionville, ON L3R 7N8
Canada
581,250
*
581,250
*
0
0
%
Marc J. Oppenheimer
(2)
Director, formerly President and CEO and Vice Chairman
466 Golf Course Drive
Leonia, NJ  07605
United States
2,689,685
•%
2,409,775
1.37%
279,910
*
Michael Brown
(2)
Director
40 Hillhurst Blvd.
Toronto, ON M5N 1N6
Canada
238,321
*
238,321
*
0
0
%
C. William Longden
(2)
Director
#32B-32 McMurrich Street
Toronto, ON M5R 2A2
Canada
442,389
*
438,389
*
4,000
*
David I. Matheson
(2), (4)
Formerly, Director
201 Corleigh Blvd.
Toronto, ON M5N 1P6
Canada
368,040
*
368,040
*
0
0
%
Harry J. Near
(2)
Director
551 Mariposa Avenue
Ottawa, ON K1M 0S5
Canada
966,229
*
996,229
*
0
0
%
Armando F. Zullo
(2)
Director
1349 Mathers Avenue
W. Vancouver
British Columbia V7T 2G5
Canada
374,877
*
374,877
*
0
0
%
16
Back to Contents
Johan van't Hof
(2)
Director
47 Golfdale Road
Toronto, ON M4N 2B5
Canada
214,775
*
214,775
*
0
0
%
Daniel R. Ross
(2)
Executive Vice President
and Corporate Counsel,
formerly, Director
Unit 1030
400 Walmer Road
Toronto, ON M5P 2X7
Canada
868,751
*
868,751
*
0
0
%
Borden D. Rosiak
(2)
Chief Financial Officer
16 Swiftdale Place
Toronto, ON M3B 1M4
Canada
230,000
*
230,000
*
0
0
%
Kenneth Thomas
(2)
Chief Operating Officer
2005 Heartwood Court
Mississauga, ON L5C 4P7
Canada
130,000
*
130,000
*
0
0
%
Sadek El Alfy
(2)
Vice President – Operations
P.O. Box 3368
Redmond, WA 98073
United States
314,677
*
282,000
*
32,677
*
Dr. Luca Riccio
Formerly, Vice President – Explorations
5403 Molina Road
N. Vancouver, British Columbia
V7R 4P5
218,000
(2)
*
3,000
(5)
*
215,000
(2)
*
Richard Marshall
Vice President – Investor Relations
515 Stonebrook Farms Drive
Alpharetta, GA 30004
United States
672,500
(2)
*
235,000
(5)
*
437,500
*
17
Back to Contents
Maria Spencer Amaro
Former employee
333 Willow Street
Apartment 102
Teaneck, NJ 07666
United States
2,800
(5)
*
2,800
(5)
*
0
0
%
Andrea Maria Boltz
Manager of Investor Relations
2514 E. Montecito Avenue
Phoenix, AZ 85016
United States
41,000
(2)
*
4,000
(5)
*
37,000
(2)
*
___
____
*  Less than 1%.
1
Assumes that the selling shareholders exercise all of their options into common shares.  (
See
"Securities Being Offered.")
2
Includes shares issuable upon the exercise of options.
3
Mr. Fung has also performed investment banking services for Crystallex.
4
Mr. Matheson is a member of McMillan Binch Mendelsohn LLP, counsel to Crystallex.  His term of office as a director expired on June 24, 2005.
See
"Legal Matters."
5
Does not include shares issuable upon the exercise of options.
18
Back to Contents
LEGAL MATTERS
Daniel R. Ross, Crystallex's Executive
    Vice President and Corporate Counsel, has issued a legal opinion that the
    common shares offered under this prospectus, when issued as described herein,
    will
    be legally
    issued
    as fully
    paid and
    non-assessable shares in the capital of Crystallex. As of June 24, 2005,
    Mr. Ross owned less than one percent of the outstanding Crystallex comm shares.
    See "Selling Sharehodlers." McMillan Binch Mendelsohn LLP has also advised
    Crystallex on matters set forth in "Enforceability of Civil Liabilities
    Against Crystallex."  As
    of June 24, 2005, partners and associates of McMillan Binch Mendelsohn LLP
    owned, in the aggregate, less than one percent of the outstanding Crystallex
    common
    shares. See "Selling
Shareholders." David I. Matheson, counsel to the firm, was a member of Crystallex's
    Board of Directors until his term of office ended on June 24, 2005, and is
    also listed as a selling shareholder herein.
See
"Selling
Shareholders."
EXPERTS
The consolidated financial statements incorporated by reference in this prospectus from Crystallex International Corporation's Annual Report on Form 40-F for the year ended December 31, 2004, have been audited by Deloitte & Touche LLP, Independent Registered Chartered Accountants, as stated in their report, which is incorporated herein by reference, and has been so incorporated in reliance upon the report of such firm given upon their authority as experts in accounting and auditing.  Deloitte & Touche LLP's address is BCE Place, 181 Bay Street, Suite 1400, Toronto, Ontario  M5J 2V1, Canada.
This registration statement and prospectus contain one or more statements, reports, or other information attributed to each of the following persons as experts in the field of mining engineering:
•
Mine Development Associates, 210 South Rock Boulevard, Reno, Nevada  89502
•
Dr. Luca Riccio, P. Geo., 5403 Molina Rd., North Vancouver, BC, V7 4P5 Canada
•
SNC-Lavalin Engineers & Constructors Inc., 2200 Lakeshore Blvd., Toronto, Ontario, Canada  M8V 1A4.
The statements, reports, or other information from Mine Development Associates, Dr. Luca Riccio, P. Geo., and SNC-Lavalin Engineers & Constructors Inc. which are attributed to any of these experts are used in this registration statement and prospectus with the consent of each of these experts to which these statements, reports, or other information are attributed.
[Remainder of page intentionally blank]
19
Back to Contents
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3.     Incorporation of Documents by Reference.
The following documents filed by Crystallex International Corporation are incorporated by reference into this Registration Statement:
(a)      Crystallex's Annual Report on Form 40-F and on Form 40-F/A – No. 1 for the fiscal year ended December 31, 2004, filed under Section 13 of the Securities Exchange Act.
(b)      The description of Crystallex's common shares without par value contained in Crystallex's registration statement under Section 12(b) of the Securities Exchange Act on Form 8-A (Registration No. 1-14620).
(c)      Crystallex's registration statement under Section 12(b) of the Securities Exchange Act on Form 8-A of rights to acquire Crystallex's common shares (Registration No. 1-14620).
(d)      The Report of Foreign Issuer on Form 6-K furnished to the SEC on April 1, 2005, on May 12, 2005, on May 13, 2005, on May 20, 2005, on June 22, 2005,
and on June 24, 2005.  Crystallex's report on Form 6-K furnished on May 12, 2005, contains its unaudited financial statements for the quarter ended March 31, 2005.
(e)      All subsequent annual reports filed by Crystallex on Form 20-F, Form 40-F, or Form 10-K, and all subsequent filings on Forms 10-Q and 8-K filed by Crystallex under Sections 12, 13, 14 or 15(d) of the Securities Exchange Act, after the date of this prospectus and before the termination of the offering are deemed incorporated by reference into and be a part of this prospectus from the date of filing such documents.
Crystallex may incorporate by reference into this prospectus any Form 6-K that it furnishes to the SEC under Sections 12, 13, 14 or 15(d) of the Securities Exchange Act after the date of this prospectus and before the offering is completed, and make that Form 6-K a part of this prospectus from the date it files the form, but only to the extent that Crystallex identifies in the Form 6-K that it is being incorporated by reference into this prospectus.
Crystallex will provide to each person, including any beneficial owner, to whom a prospectus is delivered, a copy of any or all of the information that Crystallex incorporates by reference in this prospectus but is not delivered with the prospectus, free of charge by contacting Crystallex's Secretary, Daniel R. Ross, orally or in writing, at our principal offices, which are located at 18 King Street East, Suite 1210, Toronto, Ontario, M5C 1C4, telephone number (416) 203-2448, or by contacting investor relations at
info@crystallex.com
.  However, Crystallex will not provide a copy of exhibits to items that it incorporates by reference unless it specifically incorporates those exhibits by reference.
II-1
Back to Contents
Item 4.     Description of Securities.
Not applicable.
Item 5.     Interests of Named Experts and Counsel.
McMillan Binch Mendelsohn LLP has issued a legal opinion that the common shares offered under this prospectus, when issued as described herein, will be legally issued as fully paid and non-assessable shares in the capital of Crystallex and has also advised Crystallex on matters set forth in "Enforceability of Civil Liabilities Against Crystallex."  As of May 1, 2005, partners and associates of McMillan Binch Mendelsohn LLP owned, in the aggregate, less than one percent of the outstanding Crystallex common shares.  David I. Matheson, counsel to the firm, was a member of Crystallex's Board of Directors until his term of office ended on June 24, 2005, and is also listed as a selling shareholder herein.
See
"Selling
Shareholder."
Item 6.     Indemnification of Directors and Officers.
Under the Canadian Business Corporation Act ("CBCA"), in exercising their powers and performing their functions, each member of Crystallex's Board of Directors is required to act honestly and in good faith and with a view to the best interests of Crystallex.  Under the CBCA, Crystallex has broad power to indemnify, and under certain circumstances is required to indemnify, its directors and officers against liabilities that they may incur while serving as directors or officers of Crystallex, including liabilities arising under the Securities Act, provided that they acted honestly and in good faith with a view to the best interests of Crystallex, and, in the case of a criminal or administrative action or proceeding that is
enforced by a monetary penalty, they had reasonable grounds for believing the conduct was lawful.
In addition, Crystallex has agreed to indemnify each of Crystallex's directors against any liabilities arising from his actions in his capacity with Crystallex, provided that he acted honestly and in good faith with a view to the best interests of Crystallex and, in the case of a criminal or administrative act or proceeding that is enforced by a monetary penalty, he had reasonable grounds for believing that his conduct was lawful.  Crystallex maintains directors and officers liability insurance.  Crystallex has also agreed to indemnify Marc J. Oppenheimer (at the time of such agreement, Crystallex's President, Chief Executive Officer, and a director, and, since September 2003, a Crystallex director) against any liabilities arising
from his acting in his capacity with Crystallex to the fullest extent permitted under the Business Corporation Act of New Jersey (the state where Mr. Oppenheimer resides) or the laws of Canada.
Crystallex also maintains an insurance policy for directors and officers insuring them against certain liabilities incurred by them in the performances of their duties, including liabilities under the Securities Act.
II-2
Back to Contents
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, Crystallex has been advised that in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.  In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of Crystallex in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being
registered, Crystallex will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
Item 7.  Exemption from Registration Claimed.
The restricted securities to be reoffered or resold pursuant to this registration statement were issued to Crystallex's then chief executive officer registrant, to the executive assistant to Crystallex's then-chief executive officer as of the date of the grant of options, to Crystallex's Vice President – Exploration and to its Vice President – Investor Relations, and to its Manager of Investor Relations, pursuant to Section 4(2) of and Rule 506 under the Securities Act of 1933, as amended.
Item 8.     Exhibits.
The following are filed herewith as part of this Registration Statement:
Exhibit No.
Exhibit
5
Opinion of Daniel R. Ross as to the legality of the securities being registered
23.1
Consent of Deloitte & Touche LLP
23.2
The consent of Daniel R. Ross is included in its opinion filed herewith as Exhibit 5
23.3
(1)
Consent of Mine Development Associates
23.4
(2)
Consent of Dr. Luca Riccio
23.5
Consent of SNC-Lavalin Engineers & Constructors Inc.
23.6
Consent of McMillan Binch Mendelsohn
    LLP
24
Power of Attorney (contained as part of the Signature Pages)
II-3
Back to Contents
99.1
Incentive Share Option Plan,
        as amended in 2005 (subject to shareholder approval)
99.2
Directors Remuneration Plan,
        as amended and restated as of January 1, 2005
99.3
Share Option Agreement dated
        as of November 10, 1997, between the Registrant and Robert J. Fung, together
        with Option Amending Agreement dated as of December 21, 1998, between
        the Registrant and Mr. Fung and
        schedule
        of
        substantially
        similar agreements between the Registrant and Harry J. Near and the Registrant
        and Daniel R. Ross
99.4
Share Option Agreement dated
        as of March 10, 1997, between the Registrant and Marc J. Oppenheimer,
        together with
        Option
        Amending
        Agreement
        dated as of December 21, 1998, between the Registrant and Mr. Oppenheimer
___
____
(1)
Filed as Exhibit 23.3 with Pre-Effective Amendment No. 1 to Registration Statement No. 333-13838, filed on October 19, 2001.
(2)
Filed as Exhibit 23.4 with Annual Report on Form 40-F for the year ended December 31, 2004, filed on March 31, 2004.
Item 9.     Undertakings.
(a)
The undersigned registrant hereby
    undertakes:
(1)
To file, during any period in
      which offers or sales are being made, a post-effective amendment to this
    Registration Statement:
(i)  To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent
no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement;
II-4
Back to Contents
(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
Provided, however
, That paragraphs (a)1(i) and (a)(1)(ii) of this section do not apply if the registration statement is on Form S-3, Form S-8 or Form F-3, and the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement.
(2)      That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3)      To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(b)      The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(h)      Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
II-5
Back to Contents
SIGNATURES
Pursuant to the requirements of the
    Securities Act of 1933, the registrant certifies that it has reasonable grounds
    to believe that it meets all of the requirements for filing on Form S-8 and
    has duly caused this Registration Statement to be signed on its behalf by
    the undersigned, thereunto duly authorized, in the City of Toronto, Province
    of Ontario, Canada, on this 24
th
day of June, 2005.
CRYSTALLEX INTERNATIONAL CORPORATION
By:
/s/ Todd Bruce
Todd Bruce
President, Principal Executive Officer and Director
Date:
June 24, 2005
By:
/s/
Marc
    J. Oppenheimer
Marc J. Oppenheimer
Director
and Authorized Representative in the United States
Date:
June 24, 2005
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Todd Bruce or Marc J. Oppenheimer, or any one of them, his or her attorney-in-fact, with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Registration Statement on Form S-8, and to file same, with exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact, or his or her substitute or substitutes, may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
[signatures begin on next page]
II-6
Back to Contents
Signature
Title
Date
/s/ Robert A. Fung
Chairman and Director
June 24, 2005
Robert A. Fung
/s/ Todd Bruce
President, Principal
June 24, 2005
Executive Officer and
Todd Bruce
Director
/s/ Marc J. Oppenheimer
Director
June 24, 2005
Marc J. Oppenheimer
/s/ Michael Brown
Director
June 24, 2005
Michael Brown
/s/ C. William Longden
Director
June 24, 2005
C. William Longden
/s/ Harry J. Near
Director
June 24, 2005
Harry J. Near
/s/ Armando F. Zullo
Director
June 24, 2005
Armando F. Zullo
/s/ Johan C. Van't Hof
Director
June 24, 2005
Johan C. Van't Hof
/s/ Borden D. Rosiak
Principal Financial Officer
June 24, 2005
Borden D. Rosiak
and Principal Accounting Officer
II-7
Back to Contents
EXHIBIT INDEX
The following exhibits are filed herewith as part of this Registration Statement:
Exhibit No.
Exhibit
5
Opinion of Daniel R. Ross as to the legality of the securities being registered
23.1
Consent of Deloitte & Touche
        LLP
23.2
The consent of Daniel R. Ross is included in its opinion filed herewith as Exhibit 5
23.3
(1)
Consent of Mine Development
        Associates
23.4
(2)
Consent of Dr. Luca Riccio
23.5
Consent of SNC-Lavalin Engineers & Constructors
        Inc.
23.6
Consent of McMillan Binch Mendelsohn, LLP
24
Power of Attorney (contained
        as part of the Signature Pages)
99.1
Incentive Share Option Plan,
        as amended in 2005 (subject to shareholder approval)
99.2
Directors Remuneration Plan,
        as amended and restated as of January 1, 2005
99.3
Share Option Agreement dated
        as of November 10, 1997, between the Registrant and Robert J. Fung, together
        with Option Amending Agreement dated as of December
        21, 1998, between the Registrant and Mr. Fung and schedule of substantially
        similar agreements between the Registrant and Harry J. Near and the Registrant
        and Daniel R. Ross
99.4
Share Option Agreement dated
        as of March 10, 1997, between the
        Registrant and Marc J. Oppenheimer, together with Option Amending Agreement
        dated as of December 21, 1998, between the Registrant and Mr. Oppenheimer
_____
(1)
Filed as Exhibit 23.3 with Pre-Effective Amendment No. 1 to Registration Statement No. 333-13838, filed on October 19, 2001.
(2)
Filed as Exhibit 23.4 with Annual Report on Form 40-F for the year ended December 31, 2004, filed on March 31, 2004.
II-8